NZ623216B2 - Pyrrolobenzodiazepines and targeted conjugates - Google Patents
Pyrrolobenzodiazepines and targeted conjugates Download PDFInfo
- Publication number
- NZ623216B2 NZ623216B2 NZ623216A NZ62321612A NZ623216B2 NZ 623216 B2 NZ623216 B2 NZ 623216B2 NZ 623216 A NZ623216 A NZ 623216A NZ 62321612 A NZ62321612 A NZ 62321612A NZ 623216 B2 NZ623216 B2 NZ 623216B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- compound according
- unit
- attachment
- groups
- Prior art date
Links
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- 125000003118 aryl group Chemical group 0.000 claims abstract description 81
- 125000001424 substituent group Chemical group 0.000 claims abstract description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- -1 4-carboxy-phenyl Chemical group 0.000 claims description 103
- 230000027455 binding Effects 0.000 claims description 103
- 239000003814 drug Substances 0.000 claims description 94
- 239000003446 ligand Substances 0.000 claims description 93
- 229940079593 drugs Drugs 0.000 claims description 77
- 125000005647 linker group Chemical group 0.000 claims description 70
- 108090001123 antibodies Proteins 0.000 claims description 62
- 102000004965 antibodies Human genes 0.000 claims description 62
- 239000011780 sodium chloride Substances 0.000 claims description 51
- 125000000623 heterocyclic group Chemical group 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 239000012453 solvate Substances 0.000 claims description 42
- 108010016626 Dipeptides Proteins 0.000 claims description 40
- 239000000427 antigen Substances 0.000 claims description 28
- 102000038129 antigens Human genes 0.000 claims description 28
- 108091007172 antigens Proteins 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 150000001413 amino acids Chemical group 0.000 claims description 25
- 125000004429 atoms Chemical group 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 125000002947 alkylene group Chemical group 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 230000002062 proliferating Effects 0.000 claims description 15
- 150000001768 cations Chemical class 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000005842 heteroatoms Chemical group 0.000 claims description 9
- 206010003816 Autoimmune disease Diseases 0.000 claims description 8
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 5
- 206010024324 Leukaemias Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 206010066476 Haematological malignancy Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims description 2
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 201000005216 brain cancer Diseases 0.000 claims description 2
- 230000002496 gastric Effects 0.000 claims description 2
- 201000003741 gastrointestinal carcinoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000001539 ovarian carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2S)-2-amino-3-phenylpropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 125000003875 hemiaminal group Chemical group 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 32
- 230000015572 biosynthetic process Effects 0.000 abstract description 26
- 230000002194 synthesizing Effects 0.000 abstract description 25
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000001472 cytotoxic Effects 0.000 abstract description 3
- 239000000178 monomer Substances 0.000 abstract description 3
- 150000002500 ions Chemical class 0.000 abstract 1
- 210000004027 cells Anatomy 0.000 description 58
- 239000000562 conjugate Substances 0.000 description 57
- 229920002857 polybutadiene Polymers 0.000 description 53
- 238000006243 chemical reaction Methods 0.000 description 49
- 239000000203 mixture Substances 0.000 description 41
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 36
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 35
- 239000011230 binding agent Substances 0.000 description 29
- 125000006239 protecting group Chemical group 0.000 description 29
- 239000000539 dimer Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 125000000524 functional group Chemical group 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- 125000003277 amino group Chemical group 0.000 description 21
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 21
- 125000004432 carbon atoms Chemical group C* 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 19
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 18
- 102000005600 Cathepsins Human genes 0.000 description 16
- 108010084457 Cathepsins Proteins 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
- 238000007792 addition Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 13
- 125000003396 thiol group Chemical group [H]S* 0.000 description 13
- ZALBOCCRYSQGCS-UHFFFAOYSA-N amino trifluoromethanesulfonate Chemical compound NOS(=O)(=O)C(F)(F)F ZALBOCCRYSQGCS-UHFFFAOYSA-N 0.000 description 12
- 239000000611 antibody drug conjugate Substances 0.000 description 12
- 108091008116 antibody drug conjugates Proteins 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 12
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 12
- 102100005830 CD70 Human genes 0.000 description 11
- 101700017377 CD70 Proteins 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 230000003115 biocidal Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 10
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 10
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 10
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 10
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 10
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 229940079866 intestinal antibiotics Drugs 0.000 description 10
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 10
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 230000001808 coupling Effects 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 125000001544 thienyl group Chemical group 0.000 description 8
- 229920002574 CR-39 Polymers 0.000 description 7
- 125000003368 amide group Chemical group 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 230000001681 protective Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 108060005723 speA Proteins 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 101700036477 FOLH1 Proteins 0.000 description 6
- 102100008453 FOLH1 Human genes 0.000 description 6
- 125000002723 alicyclic group Chemical group 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 150000002466 imines Chemical class 0.000 description 6
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 5
- 150000002019 disulfides Chemical class 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 5
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001409 amidines Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000000155 isotopic Effects 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 108010045030 monoclonal antibodies Proteins 0.000 description 4
- 102000005614 monoclonal antibodies Human genes 0.000 description 4
- 125000002524 organometallic group Chemical group 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 201000010874 syndrome Diseases 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 3
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 3
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 102100005826 CD19 Human genes 0.000 description 3
- 101700087100 CD19 Proteins 0.000 description 3
- 206010011715 Cyclitis Diseases 0.000 description 3
- 108010024212 E-Selectin Proteins 0.000 description 3
- 102100009835 EPHB2 Human genes 0.000 description 3
- 108010055334 EphB2 Receptor Proteins 0.000 description 3
- 102100014519 GPNMB Human genes 0.000 description 3
- 101700040370 GPNMB Proteins 0.000 description 3
- 229940097043 Glucuronic Acid Drugs 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 102100000165 MS4A1 Human genes 0.000 description 3
- 101710010909 MS4A1 Proteins 0.000 description 3
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 3
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
- 102100017963 PSCA Human genes 0.000 description 3
- 101700038464 PSCA Proteins 0.000 description 3
- AQSJGOWTSHOLKH-UHFFFAOYSA-N Phosphite Chemical compound [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 3
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 3
- 102100003520 SELE Human genes 0.000 description 3
- 101700073629 TDGF1 Proteins 0.000 description 3
- 102100018591 TMEFF2 Human genes 0.000 description 3
- 101710023903 TMEFF2 Proteins 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 150000001491 aromatic compounds Chemical class 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 150000001767 cationic compounds Chemical class 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000002993 cycloalkylene group Chemical group 0.000 description 3
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 125000002587 enol group Chemical group 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 150000002373 hemiacetals Chemical class 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229910001411 inorganic cation Inorganic materials 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 229920001690 polydopamine Polymers 0.000 description 3
- 201000004681 psoriasis Diseases 0.000 description 3
- 239000001187 sodium carbonate Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- BUUPQKDIAURBJP-UHFFFAOYSA-M sulfinate Chemical compound [O-]S=O BUUPQKDIAURBJP-UHFFFAOYSA-M 0.000 description 3
- IWOKCMBOJXYDEE-UHFFFAOYSA-N sulfinylmethane Chemical compound C=S=O IWOKCMBOJXYDEE-UHFFFAOYSA-N 0.000 description 3
- 125000004354 sulfur functional group Chemical group 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 3
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 2
- 206010001890 Alveolitis allergic Diseases 0.000 description 2
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 2
- 206010004161 Basedow's disease Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 2
- 102000007499 CD27 Ligand Human genes 0.000 description 2
- 108010046080 CD27 Ligand Proteins 0.000 description 2
- 102000004652 CD56 Antigen Human genes 0.000 description 2
- 108010003639 CD56 Antigen Proteins 0.000 description 2
- 102000000796 CD79 Antigens Human genes 0.000 description 2
- 108010001445 CD79 Antigens Proteins 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-L CHEBI:8154 Chemical group [O-]P([O-])=O ABLZXFCXXLZCGV-UHFFFAOYSA-L 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 229960001231 Choline Drugs 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N Cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N Diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N Disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 2
- 206010018651 Graft versus host disease Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 201000004779 Graves' disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000006454 Hepatitis Diseases 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N Indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 108010044023 Ki-1 Antigen Proteins 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- WCJAYABJWDIZAJ-UHFFFAOYSA-N Lithium triethylborohydride Chemical compound [Li+].CC[BH-](CC)CC WCJAYABJWDIZAJ-UHFFFAOYSA-N 0.000 description 2
- 229960003194 Meglumine Drugs 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N Methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N N-Butylamine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- GTWJETSWSUWSEJ-UHFFFAOYSA-N N-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 101710024013 POU3F1 Proteins 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical compound C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 102000001613 Sialic Acid Binding Ig-like Lectin 2 Human genes 0.000 description 2
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 2
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 2
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 2
- 102000003705 Syndecan-1 Human genes 0.000 description 2
- 108090000058 Syndecan-1 Proteins 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 206010043207 Temporal arteritis Diseases 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N Tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940035504 Tromethamine Drugs 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 102100005634 WDR83OS Human genes 0.000 description 2
- 101710010435 WDR83OS Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000004036 acetal group Chemical group 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000259 anti-tumor Effects 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 125000005488 carboaryl group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 2
- 239000011615 dehydroascorbic acid Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- PWEGVZDXTQLFLQ-UHFFFAOYSA-N dioxidoboron Chemical compound [O-][B][O-] PWEGVZDXTQLFLQ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N ethyl 2-ethoxy-1,2-dihydro-1-quinolinecarboxylate Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000001976 hemiacetal group Chemical group 0.000 description 2
- 150000002374 hemiaminals Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- DBTDEFJAFBUGPP-UHFFFAOYSA-N methanethione Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 2
- 150000005217 methyl ethers Chemical class 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 150000002891 organic anions Chemical class 0.000 description 2
- 150000002892 organic cations Chemical class 0.000 description 2
- FWNSUQXHIZZNRM-UHFFFAOYSA-R palladium;triphenylphosphane;triphenylphosphanium Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 FWNSUQXHIZZNRM-UHFFFAOYSA-R 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000005545 phthalimidyl group Chemical group 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 201000009594 systemic scleroderma Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N tetrahydro-2H-thiopyran Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- ROFMCPHQNWGXGE-SFHVURJKSA-N (3S)-N-[2-[2-(dimethylamino)ethoxy]-4-(1H-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2H-chromene-3-carboxamide Chemical compound O=C([C@@H]1COC2=CC=C(C=C2C1)OC)NC(C(=C1)OCCN(C)C)=CC=C1C=1C=NNC=1 ROFMCPHQNWGXGE-SFHVURJKSA-N 0.000 description 1
- RAGFPHFDFVNLCG-INYQBOQCSA-N (6R,6aS)-2-[(2S,3R,4R,5S,6S)-3,4-dihydroxy-4,6-dimethyl-5-(methylamino)oxan-2-yl]oxy-4,6-dihydroxy-3-methyl-8-[(E)-prop-1-enyl]-5,6,6a,7-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound O[C@@H]1[C@@](O)(C)[C@@H](NC)[C@H](C)O[C@H]1OC(C(=C1O)C)=CC(C2=O)=C1N[C@H](O)[C@H]1N2C=C(\C=C\C)C1 RAGFPHFDFVNLCG-INYQBOQCSA-N 0.000 description 1
- RWZVMMQNDHPRQD-SFTDATJTSA-N (6aS)-3-[3-[[(6aS)-2-methoxy-8-methylidene-11-oxo-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-8-methylidene-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound N1=C[C@@H]2CC(=C)CN2C(=O)C(C=C2OC)=C1C=C2OCCCOC1=CC(N=C[C@H]2N(CC(=C)C2)C2=O)=C2C=C1OC RWZVMMQNDHPRQD-SFTDATJTSA-N 0.000 description 1
- JEZZKSQFJNWDCY-NSIKDUERSA-N (8Z)-2-[3,4-dihydroxy-4,6-dimethyl-5-(methylamino)oxan-2-yl]oxy-8-propylidene-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound C1=C2C(=O)N3CC(=C/CC)\CC3C=NC2=CC=C1OC1OC(C)C(NC)C(C)(O)C1O JEZZKSQFJNWDCY-NSIKDUERSA-N 0.000 description 1
- GYUDGZRJHSDPLH-SGAXSIHGSA-N (8Z)-8-ethylidene-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound C1=NC2=CC=CC=C2C(=O)N2CC(=C/C)\CC21 GYUDGZRJHSDPLH-SGAXSIHGSA-N 0.000 description 1
- VMOHRPRQENZZPX-GQCTYLIASA-N (E)-3-(4,6-dihydroxy-3-methyl-11-oxo-5,6,6a,9-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl)-N-methylprop-2-enamide Chemical compound OC1NC2=C(O)C(C)=CC=C2C(=O)N2CC(/C=C/C(=O)NC)=CC21 VMOHRPRQENZZPX-GQCTYLIASA-N 0.000 description 1
- OQMYRVPMCIOFHL-GCOHUWJYSA-N (E)-3-[(6R)-6-hydroxy-4-methoxy-11-oxo-5,6,6a,7-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]-N,N-dimethylprop-2-enamide Chemical compound N1[C@H](O)C2CC(\C=C\C(=O)N(C)C)=CN2C(=O)C2=C1C(OC)=CC=C2 OQMYRVPMCIOFHL-GCOHUWJYSA-N 0.000 description 1
- OFZYBEBWCZBCPM-UHFFFAOYSA-N 1,1-dimethylcyclobutane Chemical compound CC1(C)CCC1 OFZYBEBWCZBCPM-UHFFFAOYSA-N 0.000 description 1
- PBIJFSCPEFQXBB-UHFFFAOYSA-N 1,1-dimethylcyclopropane Chemical compound CC1(C)CC1 PBIJFSCPEFQXBB-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- PUAKTHBSHFXVAG-UHFFFAOYSA-N 1,2-dimethylcyclobutene Chemical compound CC1=C(C)CC1 PUAKTHBSHFXVAG-UHFFFAOYSA-N 0.000 description 1
- RIRARCHMRDHZAR-UHFFFAOYSA-N 1,2-dimethylcyclopentane Chemical compound CC1CCCC1C RIRARCHMRDHZAR-UHFFFAOYSA-N 0.000 description 1
- SZZWLAZADBEDQP-UHFFFAOYSA-N 1,2-dimethylcyclopentene Chemical compound CC1=C(C)CCC1 SZZWLAZADBEDQP-UHFFFAOYSA-N 0.000 description 1
- QWKHRBFLFYXNDY-UHFFFAOYSA-N 1,2-dimethylcyclopropene Chemical compound CC1=C(C)C1 QWKHRBFLFYXNDY-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-Benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N 1,3-Cyclohexadiene Chemical group C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- SHDPRTQPPWIEJG-UHFFFAOYSA-N 1-Methylcyclopropene Chemical compound CC1=CC1 SHDPRTQPPWIEJG-UHFFFAOYSA-N 0.000 description 1
- AVPHQXWAMGTQPF-UHFFFAOYSA-N 1-methylcyclobutene Chemical compound CC1=CCC1 AVPHQXWAMGTQPF-UHFFFAOYSA-N 0.000 description 1
- CTMHWPIWNRWQEG-UHFFFAOYSA-N 1-methylcyclohexene Chemical compound CC1=CCCCC1 CTMHWPIWNRWQEG-UHFFFAOYSA-N 0.000 description 1
- ATQUFXWBVZUTKO-UHFFFAOYSA-N 1-methylcyclopentene Chemical compound CC1=CCCC1 ATQUFXWBVZUTKO-UHFFFAOYSA-N 0.000 description 1
- URSPTJYSBTXILH-UHFFFAOYSA-N 1-methylidenepiperazin-1-ium-4-ide Chemical group C=[N+]1CC[N-]CC1 URSPTJYSBTXILH-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- HUEXNHSMABCRTH-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1.C1=CNC=N1 HUEXNHSMABCRTH-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 1
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
- IVCGJOSPVGENCT-UHFFFAOYSA-N 1H-pyrrolo[2,3-f]quinoline Chemical compound N1=CC=CC2=C(NC=C3)C3=CC=C21 IVCGJOSPVGENCT-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-Dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1H-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-Chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N 2-Imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M 2-chloroethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2H-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2H-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2H-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2H-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N 3,4-dihydro-2H-pyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- FXMOIYLVKOALHC-UHFFFAOYSA-N 3,9-dihydroxy-2-methoxy-6a,7,8,9-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical class N1=CC2CCC(O)N2C(=O)C2=C1C=C(O)C(OC)=C2 FXMOIYLVKOALHC-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- RELAJOWOFXGXHI-UHFFFAOYSA-N 3H-oxathiole Chemical compound C1SOC=C1 RELAJOWOFXGXHI-UHFFFAOYSA-N 0.000 description 1
- VXIKDBJPBRMXBP-UHFFFAOYSA-N 3H-pyrrole Chemical compound C1C=CN=C1 VXIKDBJPBRMXBP-UHFFFAOYSA-N 0.000 description 1
- ZBWXZZIIMVVCNZ-UHFFFAOYSA-N 4,5-dihydroacephenanthrylene Chemical compound C1=CC(CC2)=C3C2=CC2=CC=CC=C2C3=C1 ZBWXZZIIMVVCNZ-UHFFFAOYSA-N 0.000 description 1
- ZANPJXNYBVVNSD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C=C1 ZANPJXNYBVVNSD-UHFFFAOYSA-N 0.000 description 1
- WULIZEOAYMSIHS-UHFFFAOYSA-N 4-chloro-5-methylpyrrolo[3,2-d]pyrimidine-6-carbaldehyde Chemical compound C1=NC(Cl)=C2N(C)C(C=O)=CC2=N1 WULIZEOAYMSIHS-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- BBEQQKBWUHCIOU-UHFFFAOYSA-M 5-(dimethylamino)naphthalene-1-sulfonate Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S([O-])(=O)=O BBEQQKBWUHCIOU-UHFFFAOYSA-M 0.000 description 1
- GXVKHKJETWAWRR-UHFFFAOYSA-N A805143 Chemical compound C1CCNC1.C1CCNC1 GXVKHKJETWAWRR-UHFFFAOYSA-N 0.000 description 1
- SSMFXCDUJJPFBJ-UWJYBYFXSA-N ABBEYMYCIN Chemical compound CO[C@@H]1NC2=CC=CC=C2C(=O)N2C[C@@H](O)C[C@@H]12 SSMFXCDUJJPFBJ-UWJYBYFXSA-N 0.000 description 1
- CWRYPZZKDGJXCA-UHFFFAOYSA-N Acenaphthene Chemical compound C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 description 1
- 229960000583 Acetic Acid Drugs 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N Acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010062269 Adrenalitis Diseases 0.000 description 1
- 206010001843 Alport's syndrome Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N Anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N Anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 206010003486 Aspergillus infection Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N Azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- CUFNKYGDVFVPHO-UHFFFAOYSA-N Azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 1
- 108020003591 B-Form DNA Proteins 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N Benzisoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N Benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N Benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 208000003432 Bone Disease Diseases 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- CRTBNOWPBHJICM-UHFFFAOYSA-N C1=CN=CC=N1.C1=CN=CC=N1 Chemical compound C1=CN=CC=N1.C1=CN=CC=N1 CRTBNOWPBHJICM-UHFFFAOYSA-N 0.000 description 1
- YMXFJTUQQVLJEN-UHFFFAOYSA-N C1=CN=CN=C1.C1=CN=CN=C1 Chemical compound C1=CN=CN=C1.C1=CN=CN=C1 YMXFJTUQQVLJEN-UHFFFAOYSA-N 0.000 description 1
- GUVKYQNSMXSMMU-UHFFFAOYSA-N C1CCOCC1.C1CCOCC1 Chemical compound C1CCOCC1.C1CCOCC1 GUVKYQNSMXSMMU-UHFFFAOYSA-N 0.000 description 1
- UBRJWPDONDYLLX-UHFFFAOYSA-N C1CNNC1.C1CNNC1 Chemical compound C1CNNC1.C1CNNC1 UBRJWPDONDYLLX-UHFFFAOYSA-N 0.000 description 1
- MREIFUWKYMNYTK-UHFFFAOYSA-N C=1C=CNC=1.C=1C=CNC=1 Chemical compound C=1C=CNC=1.C=1C=CNC=1 MREIFUWKYMNYTK-UHFFFAOYSA-N 0.000 description 1
- WCVXAYSKMJJPLO-UHFFFAOYSA-N C=1C=COC=1.C=1C=COC=1 Chemical compound C=1C=COC=1.C=1C=COC=1 WCVXAYSKMJJPLO-UHFFFAOYSA-N 0.000 description 1
- WEMNATFLVGEPEW-UHFFFAOYSA-N C=1C=CSC=1.C=1C=CSC=1 Chemical compound C=1C=CSC=1.C=1C=CSC=1 WEMNATFLVGEPEW-UHFFFAOYSA-N 0.000 description 1
- IEMAOEFPZAIMCN-UHFFFAOYSA-N C=1C=NNC=1.C=1C=NNC=1 Chemical compound C=1C=NNC=1.C=1C=NNC=1 IEMAOEFPZAIMCN-UHFFFAOYSA-N 0.000 description 1
- 102100000189 CD22 Human genes 0.000 description 1
- 101700020617 CD22 Proteins 0.000 description 1
- 101700017647 CD33 Proteins 0.000 description 1
- 102100016493 CD33 Human genes 0.000 description 1
- 201000002829 CREST syndrome Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 206010065917 Caplan's syndrome Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- 201000003884 Chagas disease Diseases 0.000 description 1
- 206010066261 Chronic graft versus host disease Diseases 0.000 description 1
- 206010008909 Chronic hepatitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 206010011652 Cushing's syndrome Diseases 0.000 description 1
- 208000004921 Cutaneous Lupus Erythematosus Diseases 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N Cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N Cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N Cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N Cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 229940104302 Cytosine Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-RSVSWTKNSA-N D-altro-hexose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-RSVSWTKNSA-N 0.000 description 1
- HMFHBZSHGGEWLO-ZRMNMSDTSA-N D-arabinofuranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H]1O HMFHBZSHGGEWLO-ZRMNMSDTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-gulo-Hexose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
- WQZGKKKJIJFFOK-YIDFTEPTSA-N D-ido-Hexose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-YIDFTEPTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-talose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- NFBOHOGPQUYFRF-UHFFFAOYSA-N Dibenzo-1,4-dioxin Chemical compound C1=CC=C2OC3=CC=CC=C3OC2=C1 NFBOHOGPQUYFRF-UHFFFAOYSA-N 0.000 description 1
- TXCDCPKCNAJMEE-UHFFFAOYSA-N Dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 1
- IYYZUPMFVPLQIF-UHFFFAOYSA-N Dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 1
- XTAHYROJKCXMOF-UHFFFAOYSA-N Dihydroaceanthrylene Chemical compound C1=CC=C2C(CCC3=CC=C4)=C3C4=CC2=C1 XTAHYROJKCXMOF-UHFFFAOYSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 206010013637 Dressler's syndrome Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 208000000999 Encephalomyelitis, Autoimmune, Experimental Diseases 0.000 description 1
- 206010014665 Endocarditis Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 206010014801 Endophthalmitis Diseases 0.000 description 1
- 208000006916 Eosinophilic synovitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010015251 Erythroblastosis foetalis Diseases 0.000 description 1
- 208000002621 Esophageal Motility Disorders Diseases 0.000 description 1
- 208000004332 Evans Syndrome Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108091006004 Fc-tagged proteins Proteins 0.000 description 1
- 201000004811 Felty's syndrome Diseases 0.000 description 1
- 208000001031 Fetal Erythroblastosis Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N Fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000036328 Free drug Effects 0.000 description 1
- 229960003082 Galactose Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007465 Giant Cell Arteritis Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 208000008899 Habitual Abortion Diseases 0.000 description 1
- 208000007475 Hemolytic Anemia Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 208000010159 IGA Glomerulonephritis Diseases 0.000 description 1
- 229940090034 Ibu Drugs 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N Indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N Indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 208000000509 Infertility Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N Isobenzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- BQTJMKIHKULPCZ-UHFFFAOYSA-N Isoindene Chemical compound C1=CC=CC2=CCC=C21 BQTJMKIHKULPCZ-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N Isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 201000007313 Kawasaki disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 208000006116 Lymphomatoid Granulomatosis Diseases 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N Methylcyclopentane Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- VNXBKJFUJUWOCW-UHFFFAOYSA-N Methylcyclopropane Chemical compound CC1CC1 VNXBKJFUJUWOCW-UHFFFAOYSA-N 0.000 description 1
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- LXCIHXPVYQKJAG-UHFFFAOYSA-N N-[aziridin-1-yl-(2-methylaziridin-1-yl)phosphoryl]-N-prop-2-enylprop-2-en-1-amine Chemical compound CC1CN1P(=O)(N(CC=C)CC=C)N1CC1 LXCIHXPVYQKJAG-UHFFFAOYSA-N 0.000 description 1
- 102100007544 NCAM1 Human genes 0.000 description 1
- 101700077124 NCAM1 Proteins 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 102000004459 Nitroreductases Human genes 0.000 description 1
- 108020001162 Nitroreductases Proteins 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N Norcarane Chemical compound C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 201000007142 Omenn syndrome Diseases 0.000 description 1
- 241001644482 Onyx Species 0.000 description 1
- 208000008798 Osteoma Diseases 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N Oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N Oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 101710043771 PDCL Proteins 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 206010034695 Pernicious anaemia Diseases 0.000 description 1
- XDJOIMJURHQYDW-UHFFFAOYSA-N Phenalene Chemical compound C1=CC(CC=C2)=C3C2=CC=CC3=C1 XDJOIMJURHQYDW-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- RDOWQLZANAYVLL-UHFFFAOYSA-N Phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 1
- 229950000688 Phenothiazine Drugs 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N Phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N Pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 208000009954 Pyoderma Gangrenosum Diseases 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N Pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N Pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- BBEAQIROQSPTKN-UHFFFAOYSA-N Pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- GNSXDDLDAGAXTL-UHFFFAOYSA-N S1OCCCC1.O1SCCCC1 Chemical compound S1OCCCC1.O1SCCCC1 GNSXDDLDAGAXTL-UHFFFAOYSA-N 0.000 description 1
- 102100010587 SDC1 Human genes 0.000 description 1
- 101700070405 SDC1 Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 208000005511 Schoenlein-Henoch Purpura Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 101710040533 TNFRSF8 Proteins 0.000 description 1
- 102100009538 TNFRSF8 Human genes 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 229940033123 Tannic Acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N Tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000009056 Telangiectasis Diseases 0.000 description 1
- IFLREYGFSNHWGE-UHFFFAOYSA-N Tetracene Chemical compound C1=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C21 IFLREYGFSNHWGE-UHFFFAOYSA-N 0.000 description 1
- KHVCOYGKHDJPBZ-WDCZJNDASA-N Tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N Thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N Thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N Thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N Thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N Thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N Thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- 229940113082 Thymine Drugs 0.000 description 1
- 206010043709 Thyroid disease Diseases 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 208000003441 Transfusion Reaction Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N Xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JMDNWPWLBLAQIQ-UHFFFAOYSA-N [Li+].[Li+].[Li+].[Li+].[BH4-].[BH4-].[BH4-].[BH4-] Chemical compound [Li+].[Li+].[Li+].[Li+].[BH4-].[BH4-].[BH4-].[BH4-] JMDNWPWLBLAQIQ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000002152 alkylating Effects 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000320 amidine group Chemical group 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 201000002909 aspergillosis Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 201000000936 bird fancier's lung Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 125000003865 brosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)S(*)(=O)=O 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2S)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbamate Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structures Anatomy 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- MYQCLBRBMFFFGU-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2OC=C=CC2=C1 MYQCLBRBMFFFGU-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000001651 cyanato group Chemical class [*]OC#N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 125000005725 cyclohexenylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- QTBCGUYRRXREHE-UHFFFAOYSA-N cyclopenta-1,3-diyne Chemical group C1C#CC#C1 QTBCGUYRRXREHE-UHFFFAOYSA-N 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002575 demyelinative Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 201000003066 diffuse scleroderma Diseases 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- HGGNZMUHOHGHBJ-UHFFFAOYSA-N dioxepane Chemical compound C1CCOOCC1 HGGNZMUHOHGHBJ-UHFFFAOYSA-N 0.000 description 1
- SNQXJPARXFUULZ-UHFFFAOYSA-N dioxolane Chemical compound C1COOC1 SNQXJPARXFUULZ-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 201000011191 dyskinesia of esophagus Diseases 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 230000002327 eosinophilic Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- RQIFXTOWUNAUJC-UHFFFAOYSA-M ethanesulfinate Chemical compound CCS([O-])=O RQIFXTOWUNAUJC-UHFFFAOYSA-M 0.000 description 1
- UKSVDPLOPDJECP-UHFFFAOYSA-N ethyl 3-(2H-quinolin-1-yloxy)propanoate Chemical compound C1=CC=C2N(OCCC(=O)OCC)CC=CC2=C1 UKSVDPLOPDJECP-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005703 farmer's lung Diseases 0.000 description 1
- 230000000893 fibroproliferative Effects 0.000 description 1
- 201000006353 filariasis Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002710 gonadal Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002390 hyperplastic Effects 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000004552 isoquinolin-4-yl group Chemical group C1=NC=C(C2=CC=CC=C12)* 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- AMCNGINELBODDW-UHFFFAOYSA-N lithium;triethylboron(1-) Chemical compound [Li+].CC[B-](CC)CC AMCNGINELBODDW-UHFFFAOYSA-N 0.000 description 1
- 230000002132 lysosomal Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XNEFVTBPCXGIRX-UHFFFAOYSA-M methanesulfinate Chemical compound CS([O-])=O XNEFVTBPCXGIRX-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- LBBMOAOCCQOIAQ-UHFFFAOYSA-N methoxy(phenyl)borinic acid Chemical compound COB(O)C1=CC=CC=C1 LBBMOAOCCQOIAQ-UHFFFAOYSA-N 0.000 description 1
- BDJAEZRIGNCQBZ-UHFFFAOYSA-N methylcyclobutane Chemical compound CC1CCC1 BDJAEZRIGNCQBZ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- GHCAUEMXBSLMGU-UHFFFAOYSA-N oxadiazole;1,2,5-oxadiazole Chemical compound C=1C=NON=1.C1=CON=N1 GHCAUEMXBSLMGU-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- AZHVQJLDOFKHPZ-UHFFFAOYSA-N oxathiazine Chemical compound O1SN=CC=C1 AZHVQJLDOFKHPZ-UHFFFAOYSA-N 0.000 description 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical compound C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 201000011152 pemphigus Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- GYHHZMUNWLCUAH-UHFFFAOYSA-N phenothiazine Chemical compound C1=CC=C2[N]C3=CC=CC=C3SC2=C1 GYHHZMUNWLCUAH-UHFFFAOYSA-N 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- AWOBAJUUBWTNQC-UHFFFAOYSA-N phenylazanium;trifluoromethanesulfonate Chemical compound NC1=CC=CC=C1.OS(=O)(=O)C(F)(F)F AWOBAJUUBWTNQC-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 201000001263 psoriatic arthritis Diseases 0.000 description 1
- 150000003215 pyranoses Chemical class 0.000 description 1
- IOXGEAHHEGTLMQ-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1.C1=CC=NN=C1 IOXGEAHHEGTLMQ-UHFFFAOYSA-N 0.000 description 1
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000003607 serino group Chemical group [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 150000003451 sulfinic acid amides Chemical class 0.000 description 1
- 150000003453 sulfinic acid esters Chemical class 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 239000003447 supported reagent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 125000003666 tauryl group Chemical group [H]N([H])C([H])([H])C([H])([H])S(*)(=O)=O 0.000 description 1
- 231100001005 telangiectasia Toxicity 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 1
- 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- 125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 1
- BQAJJINKFRRSFO-UHFFFAOYSA-N thiolane Chemical compound C1CCSC1.C1CCSC1 BQAJJINKFRRSFO-UHFFFAOYSA-N 0.000 description 1
- VWTZKTSLQAAIFO-UHFFFAOYSA-N thiomorpholin-4-ylmethanone Chemical group O=[C]N1CCSCC1 VWTZKTSLQAAIFO-UHFFFAOYSA-N 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- BSUNTQCMCCQSQH-UHFFFAOYSA-N triazine Chemical compound C1=CN=NN=C1.C1=CN=NN=C1 BSUNTQCMCCQSQH-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- KQBSGRWMSNFIPG-UHFFFAOYSA-N trioxane Chemical compound C1COOOC1 KQBSGRWMSNFIPG-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
This disclosure relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates, specifically cytotoxic activity. In one embodiment, the compound is (S)-2-(4-aminophenyl)-8-(3-(((S)-2-(4-hydroxyphenyl)-7-methoxy-5-oxo-5,11a-dihydro-1H-benzo[ejpyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-7-methoxy-1H-benzo[e]pyrrolo[1,2-a][1.4]diazepin-5(11aH)-one. ion and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates, specifically cytotoxic activity. In one embodiment, the compound is (S)-2-(4-aminophenyl)-8-(3-(((S)-2-(4-hydroxyphenyl)-7-methoxy-5-oxo-5,11a-dihydro-1H-benzo[ejpyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-7-methoxy-1H-benzo[e]pyrrolo[1,2-a][1.4]diazepin-5(11aH)-one.
Description
VIA510441NZPR
304110081
PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES
The present invention relates to pyrrolobenzodiazepines (PBDs), in particular
pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2
position in each monomer unit, and their inclusion in targeted conjugates.
Background to the invention
Some pyrrolobenzodiazepines (PBDs) have the ability to recognise and bond to specific
sequences of DNA; the preferred sequence is PuGPu. The first PBD antitumour antibiotic,
anthramycin, was discovered in 1965 (Leimgruber, et al., J. Am. Chem. Soc., 87, 5793-
5795 (1965); Leimgruber, et al., J. Am. Chem. Soc., 87, 5791-5793 (1965)). Since then, a
number of naturally occurring PBDs have been reported, and numerous synthetic routes
have been developed to a variety of analogues (Thurston, et al., Chem. Rev. 1994, 433-
465 (1994); Antonow, D. and Thurston, D.E., Chem. Rev. 2011 111 (4), 2815-2864).
Family members include abbeymycin (Hochlowski, et al., J. Antibiotics, 40, 145-148
(1987)), chicamycin (Konishi, et al., J. Antibiotics, 37, 200-206 (1984)), DC-81 (Japanese
Patent 58-180 487; Thurston, et al., Chem. Brit., 26, 767-772 (1990); Bose, et al.,
Tetrahedron, 48, 751-758 (1992)), mazethramycin (Kuminoto, et al., J. Antibiotics, 33, 665-
667 (1980)), neothramycins A and B (Takeuchi, et al., J. Antibiotics, 29, 93-96 (1976)),
porothramycin (Tsunakawa, et al., J. Antibiotics, 41, 1366-1373 (1988)), prothracarcin
(Shimizu, et al, J. Antibiotics, 29, 2492-2503 (1982); Langley and Thurston, J. Org. Chem.,
52, 91-97 (1987)), sibanomicin (DC-102)(Hara, et al., J. Antibiotics, 41, 702-704 (1988);
Itoh, et al., J. Antibiotics, 41, 1281-1284 (1988)), sibiromycin (Leber, et al., J. Am. Chem.
Soc., 110, 2992-2993 (1988)) and tomamycin (Arima, et al., J. Antibiotics, 25, 437-444
(1972)). PBDs are of the general structure:
They differ in the number, type and position of substituents, in both their aromatic A rings
and pyrrolo C rings, and in the degree of saturation of the C ring. In the B-ring there is
either an imine (N=C), a carbinolamine(NH-CH(OH)), or a carbinolamine methyl ether (NH-
CH(OMe)) at the N10-C11 position which is the electrophilic centre responsible for
alkylating DNA. All of the known natural products have an (S)-configuration at the chiral
VIA510441NZPR
304110081
C11a position which provides them with a right-handed twist when viewed from the C ring
towards the A ring. This gives them the appropriate three-dimensional shape for isohelicity
with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In
Antibiotics III. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-
VanDevanter, Acc. Chem. Res., 19, 230-237 (1986)). Their ability to form an adduct in the
minor groove, enables them to interfere with DNA processing, hence their use as
antitumour agents.
It has been previously disclosed that the biological activity of these molecules can be
potentiated by joining two PBD units together through their C8/C’-hydroxyl functionalities
via a flexible alkylene linker (Bose, D.S., et al., J. Am. Chem. Soc., 114, 4939-4941 (1992);
Thurston, D.E., et al., J. Org. Chem., 61, 8141-8147 (1996)). The PBD dimers are thought
to form sequence-selective DNA lesions such as the palindromic 5’-Pu-GATC-Py-3’
interstrand cross-link (Smellie, M., et al., Biochemistry, 42, 8232-8239 (2003); Martin, C., et
al., Biochemistry, 44, 4135-4147) which is thought to be mainly responsible for their
biological activity. One example of a PBD dimmer, SG2000 (SJG-136):
OMe MeO
has recently entered Phase II clinical trials in the oncology area (Gregson, S., et al., J.
Med. Chem., 44, 737-748 (2001); Alley, M.C., et al., Cancer Research, 64, 6700-6706
(2004); Hartley, J.A., et al., Cancer Research, 64, 6693-6699 (2004)).
More recently, the present inventors have previously disclosed in ,
dimeric PBD compounds bearing C2 aryl substituents, such as SG2202 (ZC-207):
OMe MeO
ZC-207
MeO OMe
and in WO2006/111759, bisulphites of such PBD compounds, for example SG2285 (ZC-
423):
VIA510441NZPR
304110081
NaSO SO Na
OMe MeO
ZC-423
MeO OMe
These compounds have been shown to be highly useful cytotoxic agents (Howard, P.W., et
al., Bioorg. Med. Chem. (2009), 19 (22), 6463-6466, doi: 10.1016/j.bmcl.2009.09.012).
Due to the manner in which these highly potent compounds act in cross-linking DNA, these
molecules have been made symmetrically. This provides for straightforward synthesis,
either by constructing the PBD moieties simultaneously having already formed the dimer
linkage, or by reacting already constructed PBD moieties with the dimer linking group.
discloses unsymmetrical dimeric PBD compound bearing aryl groups in
the C2 position of each monomer, where one of these aryl groups bears a substituent
designed to provide an anchor for linking the compound to another moiety. Co-pending
International application , filed 15 April 2011, discloses the inclusion
of these PBD dimer compounds in targeted conjugates.
It is an object of the present invention to provide pyrrolobenzodiapine compounds, a use of
said compounds in the manufacture of a medicament for treating a proliferative disease, a
conjugate, a use of said conjugate in the manufacture of a medicament for treating a
proliferative disease or an autoimmune disease, a method of treating a non-human
mammal having a proliferative disease or an autoimmune disease and/or a drug linker. It
is a further or alternative object to at least provide the public with a useful choice.
Disclosure of the invention
The present inventors have developed further unsymmetrical dimeric PBD compounds for
inclusion in targeted conjugates, where the substituents on the C2 aryl group not bearing
the anchor for linking the compound to another moiety are different to those previously
described. These differing substituent groups may offer advantages in the preparation and
use of the compounds, particularly in their biological properties and the synthesis of
conjugates, and the biological properties of these conjugates.
VIA510441NZPR
304110081
The present invention comprises a compound with the formula I:
' 10
9' 9
11' 11
Y' Y
7' 7
12 2
6' 6
or a pharmaceutically acceptable salt or solvate thereof,
wherein:
R is of formula III:
NH NNH
wherein A is a C aryl group, X is , , or NHR , wherein R is
selected from the group consisting of H and C alkyl and either
(i) Q is a single bond, and Q is selected from the group consisting of a single bond and -
Z-(CH ) -, wherein Z is selected from a single bond, O, S and NH and n is from 1 to 3, or
(ii) Q is -CH=CH-, and Q is a single bond;
R is a C aryl group, substituted by a group selected from the group consisting of OH,
-10
CO H, and CO R , wherein R is C alkyl;
2 2 1-4
R and R are independently selected from the group consisting of H, R, OH, OR, SH, SR,
NH , NHR, NRR’, nitro, Me Sn and halo;
wherein R and R’ are independently selected from the group consisting of optionally
substituted C alkyl, C heterocyclyl and C aryl groups;
1-12 3-20 5-20
R is selected from the group consisting of H, R, OH, OR, SH, SR, NH , NHR, NRR’, nitro,
Me Sn and halo;
either:
11 A A
(a) R is H, and R is OH, OR , where R is C alkyl, or
11
(b) R and R form a nitrogen-carbon double bond between the nitrogen and carbon
atoms to which they are bound, or
11
(c) R is H and R is SO M, wherein z is 2 or 3 and M is a monovalent pharmaceutically
acceptable cation;
R ″ is a C alkylene group, optionally interrupted by one or more heteroatoms, and/or by
3-12
aromatic rings;
Y and Y’ are selected from the group consisting of O, S, and NH;
6’ 7’ 9’ 6 7 9 10’
R , R , R are selected from the same groups as R , R and R , respectively, and R and
11’ 10 11 11 11’
R are the same as R and R , wherein if R and R are SO M, each M is a
VIA510441NZPR
304110081
monovalent pharmaceutically acceptable cation or together represent a divalent
pharmaceutically acceptable cation.
A second aspect of the present invention provides the use of a compound of the first
aspect of the invention in the manufacture of a medicament for treating a proliferative
disease. The second aspect also provides a compound of the first aspect of the invention
for use in the treatment of a proliferative disease.
One of ordinary skill in the art is readily able to determine whether or not a candidate
conjugate treats a proliferative condition for any particular cell type. For example, assays
which may conveniently be used to assess the activity offered by a particular compound
are described in the examples below.
A third aspect of the present invention comprises a compound of formula II:
' 10
9' 9
11' 11
Y' Y
7' 7
12 2
6' 6
or a pharmaceutically acceptable salt or solvate thereof,
wherein:
R is of formula III:
NH NNH
where A is a C aryl group, X is , , or NHR , wherein R is
selected from the group comprising H and C alkyl and either
(i) Q is a single bond, and Q is selected from a single bond and -Z-(CH ) -, where Z is
selected from a single bond, O, S and NH and n is from 1 to 3; or
(ii) Q is -CH=CH-, and Q is a single bond;
12 O O
R is a C aryl group, substituted by a group selected from OH, CO H, CO R , where R
-10 2 2
is selected from C alkyl;
R and R are independently selected from H, R, OH, OR, SH, SR, NH , NHR, NRR’, nitro,
Me Sn and halo;
where R and R’ are independently selected from optionally substituted C alkyl, C
1-12 3-20
heterocyclyl and C aryl groups;
-20
VIA510441NZPR
304110081
R is selected from H, R, OH, OR, SH, SR, NH , NHR, NRR’, nitro, Me Sn and halo;
either:
11 O O
(a) R is carbamate nitrogen protecting group, and R is O-Prot , wherein Prot is an
oxygen protecting group; or
11
(b) R is a hemi-aminal nitrogen protecting group and R is an oxo group;
R ″ is a C alkylene group, which chain may be interrupted by one or more heteroatoms,
3-12
N2 N2
e.g. O, S, NR (where R is H or C alkyl), and/or aromatic rings, e.g. benzene or
pyridine;
Y and Y’ are selected from O, S, or NH;
6’ 7’ 9’ 6 7 9 10’
R , R , R are selected from the same groups as R , R and R respectively and R and
11’ 10 11
R are the same as R and R .
A fourth aspect of the present invention comprises a method of making a compound of
formula I, or a pharmaceutically acceptable salt or solvate thereof, from a compound of
formula II, or a pharmaceutically acceptable salt or solvate thereof, by deprotection of the
imine bond.
The unsymmetrical dimeric PBD compounds of the present invention are made by different
strategies to those previously employed in making symmetrical dimeric PBD compounds.
In particular, the present inventors have developed a method which involves adding each
each C2 substituent to a symmetrical PBD dimer core in separate method steps.
Accordingly, a fifth aspect of the present invention provides a method of making a
compound of the first or third aspect of the invention, comprising at least one of the method
steps set out below.
In a sixth aspect, the present invention relates to Conjugates comprising dimers of PBDs
linked to a targeting agent, wherein the PBD dimer is of formula I, or a pharmaceutically
acceptable salt or solvate thereof (supra).
In some embodiments, the Conjugates have the following formula IV:
L - (LU-D) (IV)
or a pharmaceutically acceptable salt or solvate thereof, wherein L is a Ligand unit (i.e., a
targeting agent), LU is a Linker unit and D is a Drug unit that is a PBD dimer (see below).
VIA510441NZPR
304110081
In some embodiments, L is a Ligand unit selected from an antibody and an antigen-binding
1 1 1
fragment of an antibody; LU is a Linker unit which is -A -L -, wherein A is selected from
the group consisting of:
wherein n is 0 to 6;
wherein n is 0 to 6;
wherein n is 0 or 1, and m is 0 to 30; and
wherein n is 0 or 1, and m is 0 to 30,
and wherein in the above A groups the asterisk indicates the point of attachment to L , the
wavy line indicates the point of attachment to the Ligand unit;
L is a peptide comprising an amino acid sequence which is cleavable by the action of an
enzyme,
p is 1 to 20; and
D is a Drug unit wherein the Drug Unit is a compound according to formula I, wherein LU is
connected to the Drug Unit via the X substituent of R .
The subscript p is from 1 to 20. Accordingly, the Conjugates comprise a Ligand unit
covalently linked to at least one Drug unit by a Linker unit. The Ligand unit, described
more fully below, is a targeting agent that binds to a target moiety. The Ligand unit can, for
example, specifically bind to a cell component (a Cell Binding Agent) or to other target
molecules of interest. Accordingly, the present invention also provides methods for the
VIA510441NZPR
304110081
treatment of, for example, various cancers and autoimmune disease. These methods
encompass the use of the Conjugates wherein the Ligand unit is a targeting agent that
specifically binds to a target molecule. The Ligand unit can be, for example, a protein,
polypeptide or peptide, such as an antibody, an antigen-binding fragment of an antibody, or
other binding agent, such as an Fc fusion protein.
In the conjugates of the present invention, the PBD dimer D is of formula I, or a
pharmaceutically acceptable salt or solvate thereof, except that X is ,
or , wherein R is selected from the group comprising H
and C alkyl, and the asterix indicates the point of attachment to the remainder of the
Drug unit and the wavy line indicates the point of attachment to the Linker Unit.
The drug loading is represented by p, the number of drug molecules per Ligand unit (e.g.,
an antibody). Drug loading may range from 1 to 20 Drug units (D) per Ligand unit (e.g., Ab
or mAb). For compositions, p represents the average drug loading of the Conjugates in the
composition, and p ranges from 1 to 20.
In some embodiments, p is from about 1 to about 8 Drug units per Ligand unit. In some
embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is from
about 2 to about 8 Drug units per Ligand unit. In some embodiments, p is from about 2 to
about 6, 2 to about 5, or 2 to about 4 Drug units per Ligand unit. In some embodiments, p
is about 2, about 4, about 6 or about 8 Drug units per Ligand unit.
The average number of Drugs units per Ligand unit in a preparation from a conjugation
reaction may be characterized by conventional means such as mass spectroscopy, ELISA
assay, and HPLC. The quantitative distribution of Conjugates in terms of p may also be
determined. In some instances, separation, purification, and characterization of
homogeneous Conjugates, where p is a certain value, from Conjugates with other drug
loadings may be achieved by means such as reverse phase HPLC or electrophoresis.
In a seventh aspect, the present invention relates to Linker-Drug compounds (i.e., Drug-
Linkers) comprising dimers of PBDs (see above) linked to a linking unit. These Drug-
VIA510441NZPR
304110081
linkers can be used as intermediates for the synthesis of Conjugates comprising dimers of
PBDs linked to a targeting agent.
These Drug-Linkers have the following formula V:
LU-D (V)
or a pharmaceutically acceptable salt or solvate thereof, wherein LU is a Linker unit and D
is a Drug unit that is a PBD dimer.
1 1 1
In some embodiments, LU is G -L , wherein G is selected from the group consisting of:
wherein n is 0 to 6;
wherein n is 0 to 6;
wherein n is 0 or 1, and m is 0 to 30; and
wherein n is 0 or 1, and m is 0 to 30;
and wherein in the above G groups the asterisk indicates the point of attachment to L ;
L comprises an amino acid sequence which is cleavable by the action of an enzyme.
VIA510441NZPR
304110081
In some embodiments D is a Drug Unit wherein the Drug Unit is a compound according to
formula I, wherein LU is connected to the Drug Unit via the X subtituent of R .
In the Drug-Linkers of the present invention, the PBD dimer D is of formula I, or a
pharmaceutically acceptable salt or solvate thereof, except that X is is ,
or , wherein R is selected from the group comprising H
and C alkyl, and the asterix indicates the point of attachment to the remainder of the
Drug unit and the wavy line indicates the point of attachment to the Linker Unit.
Figures
Fig. 1 shows the effect on tumour volume of a conjugate of the present invention at two
different doses;
Fig. 2 shows the effect on tumour volume of the same conjugate as in Figure 1 on a
different tumour.
Definitions
Pharmaceutically acceptable cations
Examples of pharmaceutically acceptable monovalent and divalent cations are discussed
in Berge, et al., J. Pharm. Sci., 66, 1-19 (1977), which is incorporated herein by reference
in its entirety and for all purposes.
The pharmaceutically acceptable cation may be inorganic or organic.
Examples of pharmaceutically acceptable monovalent inorganic cations include, but are
not limited to, alkali metal ions such as Na and K . Examples of pharmaceutically
acceptable divalent inorganic cations include, but are not limited to, alkaline earth cations
2+ 2+
such as Ca and Mg . Examples of pharmaceutically acceptable organic cations include,
but are not limited to, ammonium ion (i.e. NH ) and substituted ammonium ions (e.g.
+ + + +
NH R , NH R , NHR , NR ). Examples of some suitable substituted ammonium ions are
3 2 2 3 4
those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine,
butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine,
VIA510441NZPR
304110081
phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such
as lysine and arginine. An example of a common quaternary ammonium ion is N(CH ) .
Substituents
The phrase “optionally substituted” as used herein, pertains to a parent group which may
be unsubstituted or which may be substituted.
Unless otherwise specified, the term “substituted” as used herein, pertains to a parent
group which bears one or more substituents. The term “substituent” is used herein in the
conventional sense and refers to a chemical moiety which is covalently attached to, or if
appropriate, fused to, a parent group. A wide variety of substituents are well known, and
methods for their formation and introduction into a variety of parent groups are also well
known.
Examples of substituents are described in more detail below.
C alkyl: The term “C alkyl” as used herein, pertains to a monovalent moiety obtained
1-12 1-12
by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having
from 1 to 12 carbon atoms, which may be aliphatic or alicyclic, and which may be saturated
or unsaturated (e.g. partially unsaturated, fully unsaturated). The term “C alkyl” as used
herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a
carbon atom of a hydrocarbon compound having from 1 to 4 carbon atoms, which may be
aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated,
fully unsaturated). Similarly, the term “C alkyl” as used herein, pertains to a monovalent
moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon
compound having from 1 to 2 carbon atoms, i.e. methyl or ethyl.
Thus, the term “alkyl” includes the sub-classes alkenyl, alkynyl, cycloalkyl, etc., discussed
below.
Examples of saturated alkyl groups include, but are not limited to, methyl (C ), ethyl (C ),
propyl (C ), butyl (C ), pentyl (C ), hexyl (C ) and heptyl (C ).
3 4 5 6 7
Examples of saturated linear alkyl groups include, but are not limited to, methyl (C ), ethyl
(C ), n-propyl (C ), n-butyl (C ), n-pentyl (amyl) (C ), n-hexyl (C ) and n-heptyl (C ).
2 3 4 5 6 7
VIA510441NZPR
304110081
Examples of saturated branched alkyl groups include iso-propyl (C ), iso-butyl (C ),
sec-butyl (C ), tert-butyl (C ), iso-pentyl (C ), and neo-pentyl (C ).
4 4 5 5
C Alkenyl: The term “C alkenyl” as used herein, pertains to an alkyl group having
2-12 2-12
one or more carbon-carbon double bonds.
Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, -
CH=CH ), 1-propenyl (-CH=CH-CH ), 2-propenyl (allyl, -CH-CH=CH ), isopropenyl (1-
2 3 2
methylvinyl, -C(CH )=CH ), butenyl (C ), pentenyl (C ), and hexenyl (C ).
3 2 4 5 6
C alkynyl: The term “C alkynyl” as used herein, pertains to an alkyl group having one
2-12 2-12
or more carbon-carbon triple bonds.
Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (-C ≡CH)
and 2-propynyl (propargyl, -CH -C ≡CH).
C cycloalkyl: The term “C cycloalkyl” as used herein, pertains to an alkyl group which
3-12 3-12
is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom
from an alicyclic ring atom of a cyclic hydrocarbon (carbocyclic) compound, which moiety
has from 3 to 7 carbon atoms, including from 3 to 7 ring atoms.
Examples of cycloalkyl groups include, but are not limited to, those derived from:
saturated monocyclic hydrocarbon compounds:
cyclopropane (C ), cyclobutane (C ), cyclopentane (C ), cyclohexane (C ), cycloheptane
3 4 5 6
(C ), methylcyclopropane (C ), dimethylcyclopropane (C ), methylcyclobutane (C ),
7 4 5 5
dimethylcyclobutane (C ), methylcyclopentane (C ), dimethylcyclopentane (C ) and
6 6 7
methylcyclohexane (C );
unsaturated monocyclic hydrocarbon compounds:
cyclopropene (C ), cyclobutene (C ), cyclopentene (C ), cyclohexene (C ),
3 4 5 6
methylcyclopropene (C ), dimethylcyclopropene (C ), methylcyclobutene (C ),
4 5 5
dimethylcyclobutene (C ), methylcyclopentene (C ), dimethylcyclopentene (C ) and
6 6 7
methylcyclohexene (C ); and
saturated polycyclic hydrocarbon compounds:
norcarane (C ), norpinane (C ), norbornane (C ).
7 7 7
VIA510441NZPR
304110081
C heterocyclyl: The term “C heterocyclyl” as used herein, pertains to a monovalent
3-20 3-20
moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic
compound, which moiety has from 3 to 20 ring atoms, of which from 1 to 10 are ring
heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are
ring heteroatoms.
In this context, the prefixes (e.g. C , C , C , etc.) denote the number of ring atoms, or
3-20 3-7 5-6
range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the
term “C heterocyclyl”, as used herein, pertains to a heterocyclyl group having 5 or 6 ring
atoms.
Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived
from:
N : aziridine (C ), azetidine (C ), pyrrolidine (tetrahydropyrrole) (C ), pyrroline (e.g.,
1 3 4 5
3-pyrroline, 2,5-dihydropyrrole) (C ), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (C ),
piperidine (C ), dihydropyridine (C ), tetrahydropyridine (C ), azepine (C );
6 6 6 7
O : oxirane (C ), oxetane (C ), oxolane (tetrahydrofuran) (C ), oxole (dihydrofuran) (C ),
1 3 4 5 5
oxane (tetrahydropyran) (C ), dihydropyran (C ), pyran (C ), oxepin (C );
6 6 6 7
S : thiirane (C ), thietane (C ), thiolane (tetrahydrothiophene) (C ), thiane
1 3 4 5
(tetrahydrothiopyran) (C ), thiepane (C );
O : dioxolane (C ), dioxane (C ), and dioxepane (C );
2 5 6 7
O : trioxane (C );
N : imidazolidine (C ), pyrazolidine (diazolidine) (C ), imidazoline (C ), pyrazoline
2 5 5 5
(dihydropyrazole) (C ), piperazine (C );
N O : tetrahydrooxazole (C ), dihydrooxazole (C ), tetrahydroisoxazole (C ),
1 1 5 5 5
dihydroisoxazole (C ), morpholine (C ), tetrahydrooxazine (C ), dihydrooxazine (C ),
6 6 6
oxazine (C );
N S : thiazoline (C ), thiazolidine (C ), thiomorpholine (C );
1 1 5 5 6
N O : oxadiazine (C );
2 1 6
O S : oxathiole (C ) and oxathiane (thioxane) (C ); and,
1 1 5 6
N O S : oxathiazine (C ).
1 1 1 6
Examples of substituted monocyclic heterocyclyl groups include those derived from
saccharides, in cyclic form, for example, furanoses (C ), such as arabinofuranose,
VIA510441NZPR
304110081
lyxofuranose, ribofuranose, and xylofuranse, and pyranoses (C ), such as allopyranose,
altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose,
galactopyranose, and talopyranose.
C aryl: The term “C aryl”, as used herein, pertains to a monovalent moiety obtained
-20 5-20
by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which
moiety has from 3 to 20 ring atoms. The term “C aryl”, as used herein, pertains to a
monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of
an aromatic compound, which moiety has from 5 to 7 ring atoms and the term “C aryl”,
-10
as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom
from an aromatic ring atom of an aromatic compound, which moiety has from 5 to 10 ring
atoms. Preferably, each ring has from 5 to 7 ring atoms.
In this context, the prefixes (e.g. C , C , C , C , etc.) denote the number of ring
3-20 5-7 5-6 5-10
atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For
example, the term “C aryl” as used herein, pertains to an aryl group having 5 or 6 ring
atoms.
The ring atoms may be all carbon atoms, as in “carboaryl groups”.
Examples of carboaryl groups include, but are not limited to, those derived from benzene
(i.e. phenyl) (C ), naphthalene (C ), azulene (C ), anthracene (C ), phenanthrene (C ),
6 10 10 14 14
naphthacene (C ), and pyrene (C ).
18 16
Examples of aryl groups which comprise fused rings, at least one of which is an aromatic
ring, include, but are not limited to, groups derived from indane (e.g. 2,3-dihydro-1H-
indene) (C ), indene (C ), isoindene (C ), tetraline (1,2,3,4-tetrahydronaphthalene (C ),
9 9 9 10
acenaphthene (C ), fluorene (C ), phenalene (C ), acephenanthrene (C ), and
12 13 13 15
aceanthrene (C ).
Alternatively, the ring atoms may include one or more heteroatoms, as in “heteroaryl
groups”. Examples of monocyclic heteroaryl groups include, but are not limited to, those
derived from:
N : pyrrole (azole) (C ), pyridine (azine) (C );
1 5 6
O : furan (oxole) (C );
S : thiophene (thiole) (C );
VIA510441NZPR
304110081
N O : oxazole (C ), isoxazole (C ), isoxazine (C );
1 1 5 5 6
N O : oxadiazole (furazan) (C );
2 1 5
N O : oxatriazole (C );
3 1 5
N S : thiazole (C ), isothiazole (C );
1 1 5 5
N : imidazole (1,3-diazole) (C ), pyrazole (1,2-diazole) (C ), pyridazine (1,2-diazine) (C ),
2 5 5 6
pyrimidine (1,3-diazine) (C ) (e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C );
N : triazole (C ), triazine (C ); and,
3 5 6
N : tetrazole (C ).
Examples of heteroaryl which comprise fused rings, include, but are not limited to:
C (with 2 fused rings) derived from benzofuran (O ), isobenzofuran (O ), indole
9 1 1
(N ), isoindole (N ), indolizine (N ), indoline (N ), isoindoline (N ), purine (N ) (e.g., adenine,
1 1 1 1 1 4
guanine), benzimidazole (N ), indazole (N ), benzoxazole (N O ), benzisoxazole (N O ),
2 2 1 1 1 1
benzodioxole (O ), benzofurazan (N O ), benzotriazole (N ), benzothiofuran (S ),
2 2 1 3 1
benzothiazole (N S ), benzothiadiazole (N S);
1 1 2
C (with 2 fused rings) derived from chromene (O ), isochromene (O ), chroman
1 1
(O ), isochroman (O ), benzodioxan (O ), quinoline (N ), isoquinoline (N ), quinolizine (N ),
1 1 2 1 1 1
benzoxazine (N O ), benzodiazine (N ), pyridopyridine (N ), quinoxaline (N ), quinazoline
1 1 2 2 2
(N ), cinnoline (N ), phthalazine (N ), naphthyridine (N ), pteridine (N );
2 2 2 2 4
C (with 2 fused rings) derived from benzodiazepine (N );
11 2
C (with 3 fused rings) derived from carbazole (N ), dibenzofuran (O ),
13 1 1
dibenzothiophene (S ), carboline (N ), perimidine (N ), pyridoindole (N ); and,
1 2 2 2
C (with 3 fused rings) derived from acridine (N ), xanthene (O ), thioxanthene (S ),
14 1 1 1
oxanthrene (O ), phenoxathiin (O S ), phenazine (N ), phenoxazine (N O ), phenothiazine
2 1 1 2 1 1
(N S ), thianthrene (S ), phenanthridine (N ), phenanthroline (N ), phenazine (N ).
1 1 2 1 2 2
The above groups, whether alone or part of another substituent, may themselves optionally
be substituted with one or more groups selected from themselves and the additional
substituents listed below.
Halo: -F, -Cl, -Br, and -I.
Hydroxy: -OH.
VIA510441NZPR
304110081
Ether: -OR, wherein R is an ether substituent, for example, a C alkyl group (also referred
to as a C alkoxy group, discussed below), a C heterocyclyl group (also referred to as a
1-7 3-20
C heterocyclyloxy group), or a C aryl group (also referred to as a C aryloxy group),
3-20 5-20 5-20
preferably a C alkyl group.
Alkoxy: -OR, wherein R is an alkyl group, for example, a C alkyl group. Examples of C
1-7 1-7
alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-
propoxy), -O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec-butoxy), -O(iBu)
(isobutoxy), and -O(tBu) (tert-butoxy).
1 2 1 2
Acetal: -CH(OR )(OR ), wherein R and R are independently acetal substituents, for
example, a C alkyl group, a C heterocyclyl group, or a C aryl group, preferably a
1-7 3-20 5-20
C alkyl group, or, in the case of a “cyclic” acetal group, R and R , taken together with the
two oxygen atoms to which they are attached, and the carbon atoms to which they are
attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of acetal
groups include, but are not limited to, -CH(OMe) , -CH(OEt) , and -CH(OMe)(OEt).
Hemiacetal: -CH(OH)(OR ), wherein R is a hemiacetal substituent, for example, a C
alkyl group, a C heterocyclyl group, or a C aryl group, preferably a C alkyl group.
3-20 5-20 1-7
Examples of hemiacetal groups include, but are not limited to, -CH(OH)(OMe) and -
CH(OH)(OEt).
1 2 1 2
Ketal: -CR(OR )(OR ), where R and R are as defined for acetals, and R is a ketal
substituent other than hydrogen, for example, a C alkyl group, a C heterocyclyl group,
1-7 3-20
or a C aryl group, preferably a C alkyl group. Examples ketal groups include, but are
-20 1-7
not limited to, -C(Me)(OMe) , -C(Me)(OEt) , -C(Me)(OMe)(OEt), -C(Et)(OMe) , -
2 2 2
C(Et)(OEt) , and -C(Et)(OMe)(OEt).
Hemiketal: -CR(OH)(OR ), where R is as defined for hemiacetals, and R is a hemiketal
substituent other than hydrogen, for example, a C alkyl group, a C heterocyclyl group,
1-7 3-20
or a C aryl group, preferably a C alkyl group. Examples of hemiacetal groups include,
-20 1-7
but are not limited to, -C(Me)(OH)(OMe), -C(Et)(OH)(OMe), -C(Me)(OH)(OEt), and
-C(Et)(OH)(OEt).
Oxo (keto, -one): =O.
VIA510441NZPR
304110081
Thione (thioketone): =S.
Imino (imine): =NR, wherein R is an imino substituent, for example, hydrogen, C alkyl
group, a C heterocyclyl group, or a C aryl group, preferably hydrogen or a C alkyl
3-20 5-20 1-7
group. Examples of ester groups include, but are not limited to, =NH, =NMe, =NEt, and
=NPh.
Formyl (carbaldehyde, carboxaldehyde): -C(=O)H.
Acyl (keto): -C(=O)R, wherein R is an acyl substituent, for example, a C alkyl group (also
referred to as C alkylacyl or C alkanoyl), a C heterocyclyl group (also referred to as
1-7 1-7 3-20
C heterocyclylacyl), or a C aryl group (also referred to as C arylacyl), preferably a
3-20 5-20 5-20
C alkyl group. Examples of acyl groups include, but are not limited to, -C(=O)CH
1-7 3
(acetyl), -C(=O)CH CH (propionyl), -C(=O)C(CH ) (t-butyryl), and -C(=O)Ph (benzoyl,
2 3 3 3
phenone).
Carboxy (carboxylic acid): -C(=O)OH.
Thiocarboxy (thiocarboxylic acid): -C(=S)SH.
Thiolocarboxy (thiolocarboxylic acid): -C(=O)SH.
Thionocarboxy (thionocarboxylic acid): -C(=S)OH.
Imidic acid: -C(=NH)OH.
Hydroxamic acid: -C(=NOH)OH.
Ester (carboxylate, carboxylic acid ester, oxycarbonyl): -C(=O)OR, wherein R is an ester
substituent, for example, a C alkyl group, a C heterocyclyl group, or a C aryl group,
1-7 3-20 5-20
preferably a C alkyl group. Examples of ester groups include, but are not limited to,
-C(=O)OCH , -C(=O)OCH CH , -C(=O)OC(CH ) , and -C(=O)OPh.
3 2 3 3 3
VIA510441NZPR
304110081
Acyloxy (reverse ester): -OC(=O)R, wherein R is an acyloxy substituent, for example, a C
alkyl group, a C heterocyclyl group, or a C aryl group, preferably a C alkyl group.
3-20 5-20 1-7
Examples of acyloxy groups include, but are not limited to, -OC(=O)CH (acetoxy),
-OC(=O)CH CH , -OC(=O)C(CH ) , -OC(=O)Ph, and -OC(=O)CH Ph.
2 3 3 3 2
Oxycarboyloxy: -OC(=O)OR, wherein R is an ester substituent, for example, a C alkyl
group, a C heterocyclyl group, or a C aryl group, preferably a C alkyl group.
3-20 5-20 1-7
Examples of ester groups include, but are not limited to, -OC(=O)OCH ,
-OC(=O)OCH CH , -OC(=O)OC(CH ) , and -OC(=O)OPh.
2 3 3 3
1 2 1 2
Amino: -NR R , wherein R and R are independently amino substituents, for example,
hydrogen, a C alkyl group (also referred to as C alkylamino or di-C alkylamino), a
1-7 1-7 1-7
C heterocyclyl group, or a C aryl group, preferably H or a C alkyl group, or, in the
3-20 5-20 1-7
case of a “cyclic” amino group, R and R , taken together with the nitrogen atom to which
they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Amino groups
1 1 2
may be primary (-NH ), secondary (-NHR ), or tertiary (-NHR R ), and in cationic form, may
+ 1 2 3
be quaternary (- NR R R ). Examples of amino groups include, but are not limited to,
-NH , -NHCH , -NHC(CH ) , -N(CH ) , -N(CH CH ) , and -NHPh. Examples of cyclic amino
2 3 3 2 3 2 2 3 2
groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino,
piperazino, morpholino, and thiomorpholino.
1 2 1
Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): -C(=O)NR R , wherein R and
R are independently amino substituents, as defined for amino groups. Examples of amido
groups include, but are not limited to, -C(=O)NH , -C(=O)NHCH , -C(=O)N(CH ) ,
2 3 3 2
-C(=O)NHCH CH , and -C(=O)N(CH CH ) , as well as amido groups in which R and R ,
2 3 2 3 2
together with the nitrogen atom to which they are attached, form a heterocyclic structure as
in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and
piperazinocarbonyl.
1 2 1 2
Thioamido (thiocarbamyl): -C(=S)NR R , wherein R and R are independently amino
substituents, as defined for amino groups. Examples of amido groups include, but are not
limited to, -C(=S)NH , -C(=S)NHCH , -C(=S)N(CH ) , and -C(=S)NHCH CH .
2 3 3 2 2 3
1 2 1
Acylamido (acylamino): -NR C(=O)R , wherein R is an amide substituent, for example,
hydrogen, a C alkyl group, a C heterocyclyl group, or a C aryl group, preferably
1-7 3-20 5-20
VIA510441NZPR
304110081
hydrogen or a C alkyl group, and R is an acyl substituent, for example, a C alkyl group,
1-7 1-7
a C heterocyclyl group, or a C aryl group, preferably hydrogen or a C alkyl group.
3-20 5-20 1-7
Examples of acylamide groups include, but are not limited to, -NHC(=O)CH ,
-NHC(=O)CH CH , and -NHC(=O)Ph. R and R may together form a cyclic structure, as
in, for example, succinimidyl, maleimidyl, and phthalimidyl:
O O O O
phthalimidyl
succinimidyl maleimidyl
1 2 1 2
Aminocarbonyloxy: -OC(=O)NR R , wherein R and R are independently amino
substituents, as defined for amino groups. Examples of aminocarbonyloxy groups include,
but are not limited to, -OC(=O)NH , -OC(=O)NHMe, -OC(=O)NMe , and -OC(=O)NEt .
2 2 2
1 2 3 2 3
Ureido: -N(R )CONR R wherein R and R are independently amino substituents, as
defined for amino groups, and R is a ureido substituent, for example, hydrogen, a C alkyl
group, a C heterocyclyl group, or a C aryl group, preferably hydrogen or a C alkyl
3-20 5-20 1-7
group. Examples of ureido groups include, but are not limited to, -NHCONH , -
NHCONHMe, -NHCONHEt, -NHCONMe , -NHCONEt , -NMeCONH , -NMeCONHMe,
2 2 2
, and -NMeCONEt .
-NMeCONHEt, -NMeCONMe
Guanidino: -NH-C(=NH)NH .
Tetrazolyl: a five membered aromatic ring having four nitrogen atoms and one carbon
atom,
Imino: =NR, wherein R is an imino substituent, for example, for example, hydrogen, a C
alkyl group, a C heterocyclyl group, or a C aryl group, preferably H or a C alkyl
3-20 5-20 1-7
group. Examples of imino groups include, but are not limited to, =NH, =NMe, and =NEt.
VIA510441NZPR
304110081
Amidine (amidino): -C(=NR)NR , wherein each R is an amidine substituent, for example,
hydrogen, a C alkyl group, a C heterocyclyl group, or a C aryl group, preferably H or
1-7 3-20 5-20
a C alkyl group. Examples of amidine groups include, but are not limited to,
-C(=NH)NH , -C(=NH)NMe , and -C(=NMe)NMe .
2 2 2
Nitro: -NO .
Nitroso: -NO.
Azido: -N .
Cyano (nitrile, carbonitrile): -CN.
Isocyano: -NC.
Cyanato: -OCN.
Isocyanato: -NCO.
Thiocyano (thiocyanato): -SCN.
Isothiocyano (isothiocyanato): -NCS.
Sulfhydryl (thiol, mercapto): -SH.
Thioether (sulfide): -SR, wherein R is a thioether substituent, for example, a C alkyl group
(also referred to as a C alkylthio group), a C heterocyclyl group, or a C aryl group,
1-7 3-20 5-20
preferably a C alkyl group. Examples of C alkylthio groups include, but are not limited
1-7 1-7
to, -SCH and -SCH CH .
3 2 3
Disulfide: -SS-R, wherein R is a disulfide substituent, for example, a C alkyl group, a C
1-7 3-
heterocyclyl group, or a C aryl group, preferably a C alkyl group (also referred to
5-20 1-7
herein as C alkyl disulfide). Examples of C alkyl disulfide groups include, but are not
1-7 1-7
limited to, -SSCH and -SSCH CH .
3 2 3
VIA510441NZPR
304110081
Sulfine (sulfinyl, sulfoxide): -S(=O)R, wherein R is a sulfine substituent, for example, a C
alkyl group, a C heterocyclyl group, or a C aryl group, preferably a C alkyl group.
3-20 5-20 1-7
Examples of sulfine groups include, but are not limited to, -S(=O)CH and -S(=O)CH CH .
3 2 3
Sulfone (sulfonyl): -S(=O) R, wherein R is a sulfone substituent, for example, a C alkyl
2 1-7
group, a C heterocyclyl group, or a C aryl group, preferably a C alkyl group,
3-20 5-20 1-7
including, for example, a fluorinated or perfluorinated C alkyl group. Examples of sulfone
groups include, but are not limited to, -S(=O) CH (methanesulfonyl, mesyl), -S(=O) CF
2 3 2 3
(triflyl), -S(=O) CH CH (esyl), -S(=O) C F (nonaflyl), -S(=O) CH CF (tresyl),
2 2 3 2 4 9 2 2 3
-S(=O) CH CH NH (tauryl), -S(=O) Ph (phenylsulfonyl, besyl), 4-methylphenylsulfonyl
2 2 2 2 2
(tosyl), 4-chlorophenylsulfonyl (closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl
(nosyl), 2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalenylsulfonate
(dansyl).
Sulfinic acid (sulfino): -S(=O)OH, -SO H.
Sulfonic acid (sulfo): -S(=O) OH, -SO H.
Sulfinate (sulfinic acid ester): -S(=O)OR; wherein R is a sulfinate substituent, for example,
a C alkyl group, a C heterocyclyl group, or a C aryl group, preferably a C alkyl
1-7 3-20 5-20 1-7
group. Examples of sulfinate groups include, but are not limited to, -S(=O)OCH
(methoxysulfinyl; methyl sulfinate) and -S(=O)OCH CH (ethoxysulfinyl; ethyl sulfinate).
Sulfonate (sulfonic acid ester): -S(=O) OR, wherein R is a sulfonate substituent, for
example, a C alkyl group, a C heterocyclyl group, or a C aryl group, preferably a
1-7 3-20 5-20
C alkyl group. Examples of sulfonate groups include, but are not limited to, -S(=O) OCH
1-7 2 3
(methoxysulfonyl; methyl sulfonate) and -S(=O) OCH CH (ethoxysulfonyl; ethyl sulfonate).
2 2 3
Sulfinyloxy: -OS(=O)R, wherein R is a sulfinyloxy substituent, for example, a C alkyl
group, a C heterocyclyl group, or a C aryl group, preferably a C alkyl group.
3-20 5-20 1-7
Examples of sulfinyloxy groups include, but are not limited to, -OS(=O)CH and
-OS(=O)CH CH .
Sulfonyloxy: -OS(=O) R, wherein R is a sulfonyloxy substituent, for example, a C alkyl
2 1-7
group, a C heterocyclyl group, or a C aryl group, preferably a C alkyl group.
3-20 5-20 1-7
VIA510441NZPR
304110081
Examples of sulfonyloxy groups include, but are not limited to, -OS(=O) CH (mesylate)
and -OS(=O) CH CH (esylate).
2 2 3
Sulfate: -OS(=O) OR; wherein R is a sulfate substituent, for example, a C alkyl group, a
2 1-7
C heterocyclyl group, or a C aryl group, preferably a C alkyl group. Examples of
3-20 5-20 1-7
sulfate groups include, but are not limited to, -OS(=O) OCH and -SO(=O) OCH CH .
2 3 2 2 3
1 2 1 2
Sulfamyl (sulfamoyl; sulfinic acid amide; sulfinamide): -S(=O)NR R , wherein R and R are
independently amino substituents, as defined for amino groups. Examples of sulfamyl
groups include, but are not limited to, -S(=O)NH , -S(=O)NH(CH ), -S(=O)N(CH ) ,
2 3 3 2
-S(=O)NH(CH CH ), -S(=O)N(CH CH ) , and -S(=O)NHPh.
2 3 2 3 2
1 2 1
Sulfonamido (sulfinamoyl; sulfonic acid amide; sulfonamide): -S(=O) NR R , wherein R
and R are independently amino substituents, as defined for amino groups. Examples of
sulfonamido groups include, but are not limited to, -S(=O) NH , -S(=O) NH(CH ),
2 2 2 3
-S(=O) N(CH ) , -S(=O) NH(CH CH ), -S(=O) N(CH CH ) , and -S(=O) NHPh.
2 3 2 2 2 3 2 2 3 2 2
Sulfamino: -NR S(=O) OH, wherein R is an amino substituent, as defined for amino
groups. Examples of sulfamino groups include, but are not limited to, -NHS(=O) OH and
-N(CH )S(=O) OH.
Sulfonamino: -NR S(=O) R, wherein R is an amino substituent, as defined for amino
groups, and R is a sulfonamino substituent, for example, a C alkyl group, a C
1-7 3-20
heterocyclyl group, or a C aryl group, preferably a C alkyl group. Examples of
-20 1-7
sulfonamino groups include, but are not limited to, -NHS(=O) CH and -N(CH )S(=O) C H .
2 3 3 2 6 5
Sulfinamino: -NR S(=O)R, wherein R is an amino substituent, as defined for amino
groups, and R is a sulfinamino substituent, for example, a C alkyl group, a C
1-7 3-20
heterocyclyl group, or a C aryl group, preferably a C alkyl group. Examples of
-20 1-7
sulfinamino groups include, but are not limited to, -NHS(=O)CH and -N(CH )S(=O)C H .
3 3 6 5
Phosphino (phosphine): -PR , wherein R is a phosphino substituent, for example, -H, a C
2 1-7
alkyl group, a C heterocyclyl group, or a C aryl group, preferably -H, a C alkyl group,
3-20 5-20 1-7
or a C aryl group. Examples of phosphino groups include, but are not limited to, -PH ,
-20 2
-P(CH ) , -P(CH CH ) , -P(t-Bu) , and -P(Ph) .
3 2 2 3 2 2 2
VIA510441NZPR
304110081
Phospho: -P(=O) .
Phosphinyl (phosphine oxide): -P(=O)R , wherein R is a phosphinyl substituent, for
example, a C alkyl group, a C heterocyclyl group, or a C aryl group, preferably a
1-7 3-20 5-20
C alkyl group or a C aryl group. Examples of phosphinyl groups include, but are not
1-7 5-20
limited to, -P(=O)(CH ) , -P(=O)(CH CH ) , -P(=O)(t-Bu) , and -P(=O)(Ph) .
3 2 2 3 2 2 2
Phosphonic acid (phosphono): -P(=O)(OH) .
Phosphonate (phosphono ester): -P(=O)(OR) , where R is a phosphonate substituent, for
example, -H, a C alkyl group, a C heterocyclyl group, or a C aryl group, preferably
1-7 3-20 5-20
-H, a C alkyl group, or a C aryl group. Examples of phosphonate groups include, but
1-7 5-20
are not limited to, -P(=O)(OCH ) , -P(=O)(OCH CH ) , -P(=O)(O-t-Bu) , and -P(=O)(OPh) .
3 2 2 3 2 2 2
Phosphoric acid (phosphonooxy): -OP(=O)(OH) .
Phosphate (phosphonooxy ester): -OP(=O)(OR) , where R is a phosphate substituent, for
example, -H, a C alkyl group, a C heterocyclyl group, or a C aryl group, preferably -
1-7 3-20 5-20
H, a C alkyl group, or a C aryl group. Examples of phosphate groups include, but are
1-7 5-20
not limited to, -OP(=O)(OCH ) , -OP(=O)(OCH CH ) , -OP(=O)(O-t-Bu) , and
3 2 2 3 2 2
-OP(=O)(OPh) .
Phosphorous acid: -OP(OH) .
Phosphite: -OP(OR) , where R is a phosphite substituent, for example, -H, a C alkyl
2 1-7
group, a C heterocyclyl group, or a C aryl group, preferably -H, a C alkyl group, or a
3-20 5-20 1-7
C aryl group. Examples of phosphite groups include, but are not limited to, -OP(OCH ) ,
-20 3 2
-OP(OCH CH ) , -OP(O-t-Bu) , and -OP(OPh) .
2 3 2 2 2
1 2 1 2
Phosphoramidite: -OP(OR )-NR , where R and R are phosphoramidite substituents, for
example, -H, a (optionally substituted) C alkyl group, a C heterocyclyl group, or a C
1-7 3-20 5-20
aryl group, preferably -H, a C alkyl group, or a C aryl group. Examples of
1-7 5-20
phosphoramidite groups include, but are not limited to, -OP(OCH CH )-N(CH ) ,
2 3 3 2
-OP(OCH CH )-N(i-Pr) , and -OP(OCH CH CN)-N(i-Pr) .
2 3 2 2 2 2
VIA510441NZPR
304110081
1 2 1 2
Phosphoramidate: -OP(=O)(OR )-NR , where R and R are phosphoramidate
substituents, for example, -H, a (optionally substituted) C alkyl group, a C heterocyclyl
1-7 3-20
group, or a C aryl group, preferably -H, a C alkyl group, or a C aryl group.
-20 1-7 5-20
Examples of phosphoramidate groups include, but are not limited to, -OP(=O)(OCH CH )-
N(CH ) , -OP(=O)(OCH CH )-N(i-Pr) , and -OP(=O)(OCH CH CN)-N(i-Pr) .
3 2 2 3 2 2 2 2
Alkylene
C alkylene: The term “C alkylene”, as used herein, pertains to a bidentate moiety
3-12 3-12
obtained by removing two hydrogen atoms, either both from the same carbon atom, or one
from each of two different carbon atoms, of a hydrocarbon compound having from 3 to 12
carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which
may be saturated, partially unsaturated, or fully unsaturated. Thus, the term “alkylene”
includes the sub-classes alkenylene, alkynylene, cycloalkylene, etc., discussed below.
Examples of linear saturated C alkylene groups include, but are not limited to, -(CH ) -
3-12 2 n
where n is an integer from 3 to 12, for example, -CH CH CH - (propylene),
2 2 2
-CH CH CH CH - (butylene), -CH CH CH CH CH - (pentylene) and
2 2 2 2 2 2 2 2 2
-CH CH CH CH- CH CH CH - (heptylene).
2 2 2 2 2 2 2
Examples of branched saturated C alkylene groups include, but are not limited to,
3-12
-CH(CH )CH -, -CH(CH )CH CH -, -CH(CH )CH CH CH -, -CH CH(CH )CH -,
3 2 3 2 2 3 2 2 2 2 3 2
-CH CH(CH )CH CH -, -CH(CH CH )-, -CH(CH CH )CH -, and -CH CH(CH CH )CH -.
2 3 2 2 2 3 2 3 2 2 2 3 2
Examples of linear partially unsaturated C alkylene groups (C alkenylene, and
3-12 3-12
alkynylene groups) include, but are not limited to, -CH=CH-CH -, -CH -CH=CH -,
2 2 2
-CH=CH-CH -CH -, -CH=CH-CH -CH -CH -, -CH=CH-CH=CH-, -CH=CH-CH=CH-CH -, -
2 2 2 2 2 2
CH=CH-CH=CH-CH -CH -, -CH=CH-CH -CH=CH-, -CH=CH-CH -CH -CH=CH-, and -CH -
2 2 2 2 2 2
C ≡C-CH -.
Examples of branched partially unsaturated C alkylene groups (C alkenylene and
3-12 3-12
alkynylene groups) include, but are not limited to, -C(CH )=CH-, -C(CH )=CH-CH -,
3 3 2
-CH=CH-CH(CH )- and -C ≡C-CH(CH )-.
VIA510441NZPR
304110081
Examples of alicyclic saturated C alkylene groups (C cycloalkylenes) include, but are
3-12 3-12
not limited to, cyclopentylene (e.g. cyclopent-1,3-ylene), and cyclohexylene
(e.g. cyclohex-1,4-ylene).
Examples of alicyclic partially unsaturated C alkylene groups (C cycloalkylenes)
3-12 3-12
include, but are not limited to, cyclopentenylene (e.g. 4-cyclopenten-1,3-ylene),
cyclohexenylene (e.g. 2-cyclohexen-1,4-ylene; 3-cyclohexen-1,2-ylene; 2,5-cyclohexadien-
1,4-ylene).
Oxygen protecting group: the term “oxygen protecting group” refers to a moiety which
masks a hydroxy group, and these are well known in the art. A large number of suitable
groups are described on pages 23 to 200 of Greene, T.W. and Wuts, G.M., Protective
Groups in Organic Synthesis, 3 Edition, John Wiley & Sons, Inc., 1999, which is
incorporated herein by reference in its entirety and for all purposes. Classes of particular
interest include silyl ethers (e.g. TMS, TBDMS), substituted methyl ethers (e.g. THP) and
esters (e.g. acetate).
Carbamate nitrogen protecting group: the term “carbamate nitrogen protecting group”
pertains to a moiety which masks the nitrogen in the imine bond, and these are well known
in the art. These groups have the following structure:
R' O O
wherein R’ is R as defined above. A large number of suitable groups are described on
pages 503 to 549 of Greene, T.W. and Wuts, G.M., Protective Groups in Organic
Synthesis, 3 Edition, John Wiley & Sons, Inc., 1999, which is incorporated herein by
reference in its entirety and for all purposes.
Hemi-aminal nitrogen protecting group: the term “hemi-aminal nitrogen protecting group”
pertains to a group having the following structure:
R' O
wherein R’ is R as defined above. A large number of suitable groups are described on
pages 633 to 647 as amide protecting groups of Greene, T.W. and Wuts, G.M., Protective
VIA510441NZPR
304110081
Groups in Organic Synthesis, 3 Edition, John Wiley & Sons, Inc., 1999, which is
incorporated herein by reference in its entirety and for all purposes.
Conjugates
The present invention provides Conjugates comprising a PBD dimer connected to a Ligand
unit via a Linker unit. In one embodiment, the Linker unit includes a Stretcher unit (A), a
Specificity unit (L ), and a Spacer unit (L ). The Linker unit is connected at one end to the
Ligand unit (L) and at the other end to the PBD dimer compound (D).
In one aspect, such a Conjugate is shown below in formula IVa:
1 1 2
L- (A -L -L -D) (IVa)
a s y p
or a pharmaceutically acceptable salt or solvate thereof, wherein:
L is the Ligand unit; and
1 1 2
-A -L -L - is a Linker unit (LU), wherein:
a s y
-A - is a Stretcher unit,
a is 1 or 2,
-L - is a Specificity unit,
s is an integer ranging from 0 to 12,
-L - is a Spacer unit,
y is 0, 1 or 2;
-D is a PBD dimer; and
p is from 1 to 20.
In another aspect, such a Conjugate is shown below in formula IVb:
L
L - (A - L -D) (IVb)
a y p
Also illustrated as:
1 2 1
L - (A - L (- L ) -D) (IVb)
a y s p
or a pharmaceutically acceptable salt or solvate thereof, wherein:
L is the Ligand unit; and
1 1 2
-A -L (L )- is a Linker unit (LU), wherein:
a s y
-A - is a Stretcher unit linked to a Stretcher unit (L ),
a is 1 or 2,
VIA510441NZPR
304110081
-L - is a Specificity unit linked to a Stretcher unit (L ),
s is an integer ranging from 0 to 12,
-L - is a Spacer unit,
y is 0, 1 or 2;
-D is a PBD dimer; and
p is from 1 to 20.
Preferences
The following preferences may apply to all aspects of the invention as described above, or
may relate to a single aspect. The preferences may be combined together in any
combination.
In one embodiment, the Conjugate has the formula:
1 1 2
L- (A -L -L -D)
a s y p
L- (A -L -D)
a s p,
L- (A -L -D) or
L- (A -D)
1 1 2
or a pharmaceutically acceptable salt or solvate thereof, wherein L, A , a, L s, L ,
D, y and p are as described above.
In one embodiment, the Ligand unit (L) is a Cell Binding Agent (CBA) that specifically binds
to a target molecule on the surface of a target cell. An exemplary formula is illustrated
below:
where the asterisk indicates the point of attachment to the Drug unit (D), CBA is the
1 1 1
Cell Binding Agent, L is a Specificity unit, A is a Stretcher unit connecting L to the Cell
Binding Agent, L is a Spacer unit, which is a covalent bond, a self-immolative group or
together with -OC(=O)- forms a self-immolative group, and L is optional. -OC(=O)- may be
considered as being part of L or L , as appropriate.
VIA510441NZPR
304110081
In another embodiment, the Ligand unit (L) is a Cell Binding Agent (CBA) that specifically
binds to a target molecule on the surface of a target cell. An exemplary formula is
illustrated below:
1 1 2
CBA – A – L – L – *
a s y
where the asterisk indicates the point of attachment to the Drug unit (D), CBA is the
1 1 1
Cell Binding Agent, L is a Specificity unit, A is a Stretcher unit connecting L to the Cell
Binding Agent, L is a Spacer unit which is a covalent bond or a self-immolative group, and
a is 1 or 2, s is 0, 1 or 2, and y is 0 or 1 or 2.
In the embodiments illustrated above, L can be a cleavable Specificity unit, and may be
referred to as a “trigger” that when cleaved activates a self-immolative group (or self-
immolative groups) L , when a self-immolative group(s) is present. When the Specificity
1 1 2
unit L is cleaved, or the linkage (i.e., the covalent bond) between L and L is cleaved, the
self-immolative group releases the Drug unit (D).
In another embodiment, the Ligand unit (L) is a Cell Binding Agent (CBA) that specifically
binds to a target molecule on the surface of a target cell. An exemplary formula is
illustrated below:
|
CBA – A – L – *
where the asterisk indicates the point of attachment to the Drug (D), CBA is the Cell
1 2 1 2
Binding Agent, L is a Specificity unit connected to L , A is a Stretcher unit connecting L
to the Cell Binding Agent, L is a self-immolative group, and a is 1 or 2, s is 1 or 2, and y is
1 or 2.
In the various embodiments discussed herein, the nature of L and L can vary widely.
These groups are chosen on the basis of their characteristics, which may be dictated in
part, by the conditions at the site to which the conjugate is delivered. Where the Specificity
unit L is cleavable, the structure and/or sequence of L is selected such that it is cleaved
by the action of enzymes present at the target site (e.g., the target cell). L units that are
cleavable by changes in pH (e.g. acid or base labile), temperature or upon irradiation (e.g.
photolabile) may also be used. L units that are cleavable under reducing or oxidising
conditions may also find use in the Conjugates.
VIA510441NZPR
304110081
In some embodiments, L may comprise one amino acid or a contiguous sequence of
amino acids. The amino acid sequence may be the target substrate for an enzyme.
In one embodiment, L is cleavable by the action of an enzyme. In one embodiment, the
enzyme is an esterase or a peptidase. For example, L may be cleaved by a lysosomal
protease, such as a cathepsin.
In one embodiment, L is present and together with -C(=O)O- forms a self-immolative
group or self-immolative groups. In some embodiments, -C(=O)O- also is a self-immolative
group.
In one embodiment, where L is cleavable by the action of an enzyme and L is present,
the enzyme cleaves the bond between L and L , whereby the self-immolative group(s)
release the Drug unit.
L and L , where present, may be connected by a bond selected from:
-C(=O)NH-,
-C(=O)O-,
-NHC(=O)-,
-OC(=O)-,
-OC(=O)O-,
-NHC(=O)O-,
-OC(=O)NH-,
-NHC(=O)NH, and
-O- (a glycosidic bond).
An amino group of L that connects to L may be the N-terminus of an amino acid or may
be derived from an amino group of an amino acid side chain, for example a lysine amino
acid side chain.
A carboxyl group of L that connects to L may be the C-terminus of an amino acid or may
be derived from a carboxyl group of an amino acid side chain, for example a glutamic acid
amino acid side chain.
VIA510441NZPR
304110081
A hydroxy group of L that connects to L may be derived from a hydroxy group of an amino
acid side chain, for example a serine amino acid side chain.
In one embodiment, -C(=O)O- and L together form the group:
where the asterisk indicates the point of attachment to the Drug unit, the wavy line
indicates the point of attachment to the L , Y is -N(H)-, -O-, -C(=O)N(H)- or -C(=O)O-, and
n is 0 to 3. The phenylene ring is optionally substituted with one, two or three substituents
as described herein.
In one embodiment, Y is NH.
In one embodiment, n is 0 or 1. Preferably, n is 0.
Where Y is NH and n is 0, the self-immolative group may be referred to as a
p-aminobenzylcarbonyl linker (PABC).
The self-immolative group will allow for release of the Drug unit (i.e., the asymmetric PBD)
when a remote site in the linker is activated, proceeding along the lines shown below (for
n=0):
where the asterisk indicates the attachment to the Drug, L is the activated form of
the remaining portion of the linker and the released Drug unit is not shown. These groups
have the advantage of separating the site of activation from the Drug.
VIA510441NZPR
304110081
In another embodiment, -C(=O)O- and L together form a group selected from:
where the asterisk, the wavy line, Y, and n are as defined above. Each phenylene
ring is optionally substituted with one, two or three substituents as described herein. In one
embodiment, the phenylene ring having the Y substituent is optionally substituted and the
phenylene ring not having the Y substituent is unsubstituted.
In another embodiment, -C(=O)O- and L together form a group selected from:
where the asterisk, the wavy line, Y, and n are as defined above, E is O, S or NR, D
is N, CH, or CR, and F is N, CH, or CR.
In one embodiment, D is N.
In one embodiment, D is CH.
In one embodiment, E is O or S.
In one embodiment, F is CH.
In a preferred embodiment, the covalent bond between L and L is a cathepsin labile (e.g.,
cleavable) bond.
In one embodiment, L comprises a dipeptide. The amino acids in the dipeptide may be
any combination of natural amino acids and non-natural amino acids. In some
VIA510441NZPR
304110081
embodiments, the dipeptide comprises natural amino acids. Where the linker is a
cathepsin labile linker, the dipeptide is the site of action for cathepsin-mediated cleavage.
The dipeptide then is a recognition site for cathepsin.
In one embodiment, the group -X -X - in dipeptide, -NH-X -X -CO-, is selected from:
1 2 1 2
-Phe-Lys-,
-Val-Ala-,
-Val-Lys-,
-Ala-Lys-,
-Val-Cit-,
-Phe-Cit-,
-Leu-Cit-,
-Ile-Cit-,
-Phe-Arg-, and
-Trp-Cit-;
where Cit is citrulline. In such a dipeptide, -NH- is the amino group of X , and CO is the
carbonyl group of X .
Preferably, the group -X -X - in dipeptide, -NH-X -X -CO-, is selected from:
1 2 1 2
-Phe-Lys-,
-Val-Ala-,
-Val-Lys-,
-Ala-Lys-, and
-Val-Cit-.
Most preferably, the group -X -X - in dipeptide, -NH-X -X -CO-, is -Phe-Lys-, Val-Cit or
1 2 1 2
-Val-Ala-.
Other dipeptide combinations of interest include:
-Gly-Gly-,
-Pro-Pro-, and
-Val-Glu-.
Other dipeptide combinations may be used, including those described by Dubowchik et al.,
which is incorporated herein by reference in its entirety and for all purposes.
VIA510441NZPR
304110081
In one embodiment, the amino acid side chain is chemically protected, where appropriate.
The side chain protecting group may be a group as discussed below. Protected amino
acid sequences are cleavable by enzymes. For example, a dipeptide sequence comprising
a Boc side chain-protected Lys residue is cleavable by cathepsin.
Protecting groups for the side chains of amino acids are well known in the art and are
described in the Novabiochem Catalog. Additional protecting group strategies are set out
in Protective groups in Organic Synthesis, Greene and Wuts.
Possible side chain protecting groups are shown below for those amino acids having
reactive side chain functionality:
Arg: Z, Mtr, Tos;
Asn: Trt, Xan;
Asp: Bzl, t-Bu;
Cys: Acm, Bzl, Bzl-OMe, Bzl-Me, Trt;
Glu: Bzl, t-Bu;
Gln: Trt, Xan;
His: Boc, Dnp, Tos, Trt;
Lys: Boc, Z-Cl, Fmoc, Z;
Ser: Bzl, TBDMS, TBDPS;
Thr: Bz;
Trp: Boc;
Tyr: Bzl, Z, Z-Br.
In one embodiment, -X - is connected indirectly to the Drug unit. In such an embodiment,
the Spacer unit L is present.
In one embodiment, -X - is connected directly to the Drug unit. In such an embodiment,
the Spacer unit L is absent.
In one embodiment, the dipeptide is used in combination with a self-immolative group(s)
(the Spacer unit). The self-immolative group(s) may be connected to -X -.
VIA510441NZPR
304110081
Where a self-immolative group is present, -X - is connected directly to the self-immolative
group. In one embodiment, -X - is connected to the group Y of the self-immolative group.
Preferably the group -X -CO- is connected to Y, where Y is NH.
In one embodiment, -X - is connected directly to A . Preferably the group NH-X - (the
amino terminus of X ) is connected to A . A may comprise the functionality -CO- thereby
to form an amide link with -X -.
In one embodiment, L and L together with -OC(=O)- comprise the group -X -X -PABC-.
The PABC group is connected directly to the Drug unit. In one example, the self-
immolative group and the dipeptide together form the group -Phe-Lys-PABC-, which is
illustrated below:
O O *
where the asterisk indicates the point of attachment to the Drug unit, and the wavy
line indicates the point of attachment to the remaining portion of L or the point of
attachment to A . Preferably, the wavy line indicates the point of attachment to A .
Alternatively, the self-immolative group and the dipeptide together form the group -Val-Ala-
PABC-, which is illustrated below:
where the asterisk and the wavy line are as defined above.
In another embodiment, L and L together with -OC(=O)- represent:
VIA510441NZPR
304110081
or ,
where the asterisk indicates the point of attachment to the Drug unit, the wavy line
indicates the point of attachment to A , Y is a covalent bond or a functional group, and E is
a group that is susceptible to cleavage thereby to activate a self-immolative group.
E is selected such that the group is susceptible to cleavage, e.g., by light or by the action of
an enzyme. E may be -NO or glucuronic acid (e.g., b-glucuronic acid). The former may
be susceptible to the action of a nitroreductase, the latter to the action of a
b-glucuronidase.
The group Y may be a covalent bond.
The group Y may be a functional group selected from:
-C(=O)NH-
-C(=O)NH-,
-C(=O)O-,
-NHC(=O)-,
-OC(=O)-,
-OC(=O)O-,
-NHC(=O)O-,
-OC(=O)NH-,
-NHC(=O)NH-,
-NHC(=O)NH,
-C(=O)NHC(=O)-,
SO , and
-S-.
The group Y is preferably –NH-, -CH , -O-, and -S-.
In some embodiments, L and L together with -OC(=O)- represent:
VIA510441NZPR
304110081
where the asterisk indicates the point of attachment to the Drug unit, the wavy line
indicates the point of attachment to A, Y is a covalent bond or a functional group and E is
glucuronic acid (e.g., b-glucuronic acid). Y is preferably a functional group selected from
–NH-.
In some embodiments, L and L together represent:
where the asterisk indicates the point of attachment to the remainder of L or the
Drug unit, the wavy line indicates the point of attachment to A , Y is a covalent bond or a
functional group and E is glucuronic acid (e.g., b-glucuronic acid). Y is preferably a
functional group selected from –NH-, -CH , -O-, and -S-.
In some further embodiments, Y is a functional group as set forth above, the functional
group is linked to an amino acid, and the amino acid is linked to the Stretcher unit A . In
some embodiments, amino acid is b-alanine. In such an embodiment, the amino acid is
equivalently considered part of the Stretcher unit.
The Specificity unit L and the Ligand unit are indirectly connected via the Stretcher unit.
L and A may be connected by a bond selected from:
-C(=O)NH-,
-C(=O)O-,
-NHC(=O)-,
-OC(=O)-,
-OC(=O)O-,
-NHC(=O)O-,
VIA510441NZPR
304110081
-OC(=O)NH-, and
-NHC(=O)NH-.
In one embodiment, the group A is:
where the asterisk indicates the point of attachment to L , L or D, the wavy line
indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n
is 5.
In one embodiment, the group A is:
where the asterisk indicates the point of attachment to L , L or D, the wavy line
indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n
is 5.
In one embodiment, the group A is:
where the asterisk indicates the point of attachment to L , L or D, the wavy line
indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a
preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4
or 8.
In one embodiment, the group A is:
VIA510441NZPR
304110081
where the asterisk indicates the point of attachment to L , L or D, the wavy line
indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a
preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4
or 8.
In one embodiment, the group A is:
where the asterisk indicates the point of attachment to L , L or D, the wavy line
indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n
is 5.
In one embodiment, the group A is:
where the asterisk indicates the point of attachment to L , L or D, the wavy line
indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n
is 5.
In one embodiment, the group A is:
where the asterisk indicates the point of attachment to L , L or D, the wavy line
indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a
preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4
or 8.
In one embodiment, the group A is:
VIA510441NZPR
304110081
where the asterisk indicates the point of attachment to L , L or D, the wavy line
indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a
preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4
or 8.
In one embodiment, the connection between the Ligand unit and A is through a thiol
residue of the Ligand unit and a maleimide group of A .
In one embodiment, the connection between the Ligand unit and A is:
where the asterisk indicates the point of attachment to the remaining portion of A ,
L , L or D, and the wavy line indicates the point of attachment to the remaining portion of
the Ligand unit. In this embodiment, the S atom is typically derived from the Ligand unit.
In each of the embodiments above, an alternative functionality may be used in place of the
malemide-derived group shown below:
where the wavy line indicates the point of attachment to the Ligand unit as before,
1 1 2
and the asterisk indicates the bond to the remaining portion of the A group, or to L , L or
In one embodiment, the maleimide-derived group is replaced with the group:
VIA510441NZPR
304110081
where the wavy line indicates point of attachment to the Ligand unit, and the
1 1 2
asterisk indicates the bond to the remaining portion of the A group , or to L , L or D.
In one embodiment, the maleimide-derived group is replaced with a group, which optionally
together with a Ligand unit (e.g., a Cell Binding Agent), is selected from:
-C(=O)NH-,
-C(=O)O-,
-NHC(=O)-,
-OC(=O)-,
-OC(=O)O-,
-NHC(=O)O-,
-OC(=O)NH-,
-NHC(=O)NH-,
-NHC(=O)NH,
-C(=O)NHC(=O)-,
-S-,
-S-S-,
-CH C(=O)C(=O)CH -,
=N-NH-, and
-NH-N=.
Of these -C(=O)CH - may be preferred especially when the carbonyl group is bound to –
NH-.
In one embodiment, the maleimide-derived group is replaced with a group, which optionally
together with the Ligand unit, is selected from:
VIA510441NZPR
304110081
where the wavy line indicates either the point of attachment to the Ligand unit or the
bond to the remaining portion of the A group, and the asterisk indicates the other of the
point of attachment to the Ligand unit or the bond to the remaining portion of the A group.
Other groups suitable for connecting L to the Cell Binding Agent are described in
In one embodiment, the Stretcher unit A is present, the Specificity unit L is present and
Spacer unit L is absent. Thus, L and the Drug unit are directly connected via a bond.
Equivalently in this embodiment, L is a bond.
L and D may be connected by a bond selected from:
-C(=O)N<,
-OC(=O)N<, and
-NHC(=O)N<,
where N< is part of D.
and D are preferably connected by a bond:
In one embodiment, L
-C(=O)N<.
In one embodiment, L comprises a dipeptide and one end of the dipeptide is linked to D.
As described above, the amino acids in the dipeptide may be any combination of natural
amino acids and non-natural amino acids. In some embodiments, the dipeptide comprises
natural amino acids. Where the linker is a cathepsin labile linker, the dipeptide is the site of
action for cathepsin-mediated cleavage. The dipeptide then is a recognition site for
cathepsin.
In one embodiment, the group -X -X - in dipeptide, -NH-X -X -CO-, is selected from:
1 2 1 2
-Phe-Lys-,
-Val-Ala-,
-Val-Lys-,
-Ala-Lys-,
-Val-Cit-,
-Phe-Cit-,
-Leu-Cit-,
VIA510441NZPR
304110081
-Ile-Cit-,
-Phe-Arg-, and
-Trp-Cit-;
where Cit is citrulline. In such a dipeptide, -NH- is the amino group of X , and CO is the
carbonyl group of X .
Preferably, the group -X -X - in dipeptide, -NH-X -X -CO-, is selected from:
1 2 1 2
-Phe-Lys-,
-Val-Ala-,
-Val-Lys-,
-Ala-Lys-, and
-Val-Cit-.
Most preferably, the group -X -X - in dipeptide, -NH-X -X -CO-, is -Phe-Lys- or -Val-Ala-.
1 2 1 2
Other dipeptide combinations of interest include:
-Gly-Gly-,
-Pro-Pro-, and
-Val-Glu-.
Other dipeptide combinations may be used, including those described above.
In one embodiment, L -D is:
-NH-X -X -CO-N< *
where -NH-X -X -CO is the dipeptide, -N< is part of the Drug unit, the asterisk
indicates the points of attachment to the remainder of the Drug unit, and the wavy line
indicates the point of attachment to the remaining portion of L or the point of attachment to
A . Preferably, the wavy line indicates the point of attachment to A .
In one embodiment, the dipeptide is valine-alanine and L -D is:
VIA510441NZPR
304110081
where the asterisks, -N< and the wavy line are as defined above.
In one embodiment, the dipeptide is phenylalnine-lysine and L -D is:
where the asterisks, -N< and the wavy line are as defined above.
In one embodiment, the dipeptide is valine-citrulline.
In one embodiment, the groups A -L are:
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n
is 5.
VIA510441NZPR
304110081
In one embodiment, the groups A -L are:
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n
is 5.
In one embodiment, the groups A -L are:
N N L
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a
preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4
or 8.
In one embodiment, the groups A -L are:
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a
preferred embodiment, n is 1 and m is 0 to 10, 1 to 7, preferably 3 to 7, most preferably 3
or 7.
VIA510441NZPR
304110081
In one embodiment, the groups A -L are:
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n
is 5.
In one embodiment, the groups A -L are:
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n
is 5.
In one embodiment, the groups A -L are:
O N L
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a
preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4
or 8.
In one embodiment, the groups A -L is:
VIA510441NZPR
304110081
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a
preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4
or 8.
In one embodiment, the groups L- A -L are:
where the asterisk indicates the point of attachment to L or D, S is a sulfur group of
the Ligand unit, the wavy line indicates the point of attachment to the rest of the Ligand
unit, and n is 0 to 6. In one embodiment, n is 5.
In one embodiment, the group L-A -L are:
where the asterisk indicates the point of attachment to L or D, S is a sulfur group of
the Ligand unit, the wavy line indicates the point of attachment to the remainder of the
Ligand unit, and n is 0 to 6. In one embodiment, n is 5.
In one embodiment, the groups L-A -L are:
N N L
where the asterisk indicates the point of attachment to L or D, S is a sulfur group of
the Ligand unit, the wavy line indicates the point of attachment to the remainder of the
Ligand unit, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to
, 1 to 8, preferably 4 to 8, most preferably 4 or 8.
-L are:
In one embodiment, the groups L-A
VIA510441NZPR
304110081
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a
preferred embodiment, n is 1 and m is 0 to 10, 1 to 7, preferably 4 to 8, most preferably 4
or 8.
In one embodiment, the groups L-A -L are:
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the remainder of the Ligand unit, and n is 0 to 6. In one
embodiment, n is 5.
In one embodiment, the groups L-A -L are:
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the remainder of the Ligand unit, and n is 0 to 6. In one
embodiment, n is 5.
In one embodiment, the groups L-A -L are:
O N L
VIA510441NZPR
304110081
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the remainder of the Ligand unit, n is 0 or 1, and m is 0
to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most
preferably 4 or 8.
In one embodiment, the groups L-A -L are:
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to the remainder of the Ligand unit, n is 0 or 1, and m is 0
to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most
preferably 4 or 8.
In one embodiment, the Stretcher unit is an acetamide unit, having the formula:
-CH -CO-N-*
where the asterisk indicates the point of attachment to the remainder of the
Stretcher unit, L or D, and the wavy line indicates the point of attachment to the Ligand
unit.
Linker-Drugs
In other embodiments, Linker-Drug compounds are provided for conjugation to a Ligand
unit. In one embodiment, the Linker-Drug compounds are designed for connection to a
Cell Binding Agent.
In one embodiment, the Drug Linker compound has the formula:
L O *
where the asterisk indicates the point of attachment to the Drug unit (D, as defined
1 1 1
above), G is a Stretcher group (A ) to form a connection to a Ligand unit, L is a Specificity
unit, L (a Spacer unit) is a covalent bond or together with -OC(=O)- forms a self-
VIA510441NZPR
304110081
immolative group(s).
In another embodiment, the Drug Linker compound has the formula:
1 1 2
G -L -L -
where the asterisk indicates the point of attachment to the Drug unit (D), G is a
1 1 2
Stretcher unit (A ) to form a connection to a Ligand unit, L is a Specificity unit, L (a
Spacer unit) is a covalent bond or a self-immolative group(s).
1 2 1
L and L are as defined above. References to connection to A can be construed here as
referring to a connection to G .
In one embodiment, where L comprises an amino acid, the side chain of that amino acid
may be protected. Any suitable protecting group may be used. In one embodiment, the
side chain protecting groups are removable with other protecting groups in the compound,
where present. In other embodiments, the protecting groups may be orthogonal to other
protecting groups in the molecule, where present.
Suitable protecting groups for amino acid side chains include those groups described in the
Novabiochem Catalog 2006/2007. Protecting groups for use in a cathepsin labile linker are
also discussed in Dubowchik et al.
In certain embodiments of the invention, the group L includes a Lys amino acid residue.
The side chain of this amino acid may be protected with a Boc or Alloc protected group. A
Boc protecting group is most preferred.
The functional group G forms a connecting group upon reaction with a Ligand unit (e.g., a
cell binding agent.
In one embodiment, the functional group G is or comprises an amino, carboxylic acid,
hydroxy, thiol, or maleimide group for reaction with an appropriate group on the Ligand
unit. In a preferred embodiment, G comprises a maleimide group.
VIA510441NZPR
304110081
In one embodiment, the group G is an alkyl maleimide group. This group is suitable for
reaction with thiol groups, particularly cysteine thiol groups, present in the cell binding
agent, for example present in an antibody.
In one embodiment, the group G is:
where the asterisk indicates the point of attachment to L , L or D, and n is 0 to 6.
In one embodiment, n is 5.
In one embodiment, the group G is:
where the asterisk indicates the point of attachment to L , L or D, and n is 0 to 6.
In one embodiment, n is 5.
In one embodiment, the group G is:
where the asterisk indicates the point of attachment to L , L or D, n is 0 or 1, and m
is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 2, preferably 4 to 8, and
most preferably 4 or 8.
In one embodiment, the group G is:
VIA510441NZPR
304110081
where the asterisk indicates the point of attachment to L , L or D, n is 0 or 1, and
m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8,
and most preferably 4 or 8.
In one embodiment, the group G is:
where the asterisk indicates the point of attachment to L , L or D, and n is 0 to 6.
In one embodiment, n is 5.
In one embodiment, the group G is:
where the asterisk indicates the point of attachment to L , L or D, and n is 0 to 6.
In one embodiment, n is 5.
In one embodiment, the group G is:
where the asterisk indicates the point of attachment to L , L or D, n is 0 or 1, and m
is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 2, preferably 4 to 8, and
most preferably 4 or 8.
In one embodiment, the group G is:
VIA510441NZPR
304110081
where the asterisk indicates the point of attachment to L , L or D, n is 0 or 1, and
m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8,
and most preferably 4 or 8.
In each of the embodiments above, an alternative functionality may be used in place of the
malemide group shown below:
where the asterisk indicates the bond to the remaining portion of the G group.
In one embodiment, the maleimide-derived group is replaced with the group:
where the asterisk indicates the bond to the remaining portion of the G group.
In one embodiment, the maleimide group is replaced with a group selected from:
-C(=O)OH,
-OH,
-NH ,
-SH,
-C(=O)CH X, where X is Cl, Br or I,
-CHO,
-NHNH
-C ≡CH, and
-N (azide).
VIA510441NZPR
304110081
Of these, -C(=O)CH X may be preferred, especially when the carbonyl group is bound to –
NH-.
In one embodiment, L is present, and G is -NH , -NHMe, -COOH, -OH or -SH.
In one embodiment, where L is present, G is -NH or -NHMe. Either group may be the
N-terminal of an L amino acid sequence.
1 1 1
In one embodiment, L is present and G is -NH , and L is an amino acid sequence -X -X -
2 1 2
, as defined above.
In one embodiment, L is present and G is COOH. This group may be the C-terminal of
an L amino acid sequence.
In one embodiment, L is present and G is OH.
In one embodiment, L is present and G is SH.
The group G may be convertable from one functional group to another. In one
1 1 1
embodiment, L is present and G is -NH . This group is convertable to another group G
comprising a maleimide group. For example, the group -NH may be reacted with an acids
or an activated acid (e.g., N-succinimide forms) of those G groups comprising maleimide
shown above.
The group G may therefore be converted to a functional group that is more appropriate for
reaction with a Ligand unit.
As noted above, in one embodiment, L is present and G is -NH , -NHMe, -COOH, -OH or
-SH. In a further embodiment, these groups are provided in a chemically protected form.
The chemically protected form is therefore a precursor to the linker that is provided with a
functional group.
In one embodiment, G is -NH in a chemically protected form. The group may be
protected with a carbamate protecting group. The carbamate protecting group may be
selected from the group consisting of:
Alloc, Fmoc, Boc, Troc, Teoc, Cbz and PNZ.
VIA510441NZPR
304110081
Preferably, where G is -NH , it is protected with an Alloc or Fmoc group.
In one embodiment, where G is -NH , it is protected with an Fmoc group.
In one embodiment, the protecting group is the same as the carbamate protecting group of
the capping group.
In one embodiment, the protecting group is not the same as the carbamate protecting
group of the capping group. In this embodiment, it is preferred that the protecting group is
removable under conditions that do not remove the carbamate protecting group of the
capping group.
The chemical protecting group may be removed to provide a functional group to form a
connection to a Ligand unit. Optionally, this functional group may then be converted to
another functional group as described above.
In one embodiment, the active group is an amine. This amine is preferably the N-terminal
amine of a peptide, and may be the N-terminal amine of the preferred dipeptides of the
invention.
The active group may be reacted to yield the functional group that is intended to form a
connection to a Ligand unit.
In other embodiments, the Linker unit is a precursor to the Linker uit having an active
group. In this embodiment, the Linker unit comprises the active group, which is protected
by way of a protecting group. The protecting group may be removed to provide the Linker
unit having an active group.
Where the active group is an amine, the protecting group may be an amine protecting
group, such as those described in Green and Wuts.
The protecting group is preferably orthogonal to other protecting groups, where present, in
the Linker unit.
VIA510441NZPR
304110081
In one embodiment, the protecting group is orthogonal to the capping group. Thus, the
active group protecting group is removable whilst retaining the capping group. In other
embodiments, the protecting group and the capping group is removable under the same
conditions as those used to remove the capping group.
In one embodiment, the Linker unit is:
NHBoc
where the asterisk indicates the point of attachment to the Drug unit, and the wavy
line indicates the point of attachment to the remaining portion of the Linker unit, as
applicable or the point of attachment to G . Preferably, the wavy line indicates the point of
attachment to G .
In one embodiment, the Linker unit is:
O O *
where the asterisk and the wavy line are as defined above.
Other functional groups suitable for use in forming a connection between L and the Cell
Binding Agent are described in .
Ligand Unit
The Ligand Unit may be of any kind, and include a protein, polypeptide, peptide and a non-
peptidic agent that specifically binds to a target molecule. In some embodiments, the
Ligand unit may be a protein, polypeptide or peptide. In some embodiments, the Ligand
unit may be a cyclic polypeptide. These Ligand units can include antibodies or a fragment
of an antibody that contains at least one target molecule-binding site, lymphokines,
VIA510441NZPR
304110081
hormones, growth factors, or any other cell binding molecule or substance that can
specifically bind to a target. The ligand Unit is also referred to herein as a “binding agent”
or “targeting agent”.
The terms “specifically binds” and “specific binding” refer to the binding of an antibody or
other protein, polypeptide or peptide to a predetermined molecule (e.g., an antigen).
7 -1
Typically, the antibody or other molecule binds with an affinity of at least about 1x10 M ,
and binds to the predetermined molecule with an affinity that is at least two-fold greater
than its affinity for binding to a non-specific molecule (e.g., BSA, casein) other than the
predetermined molecule or a closely-related molecule.
Examples of Ligand units include those agents described for use in ,
which is incorporated by reference herein in its entirety and for all purposes.
In some embodiments, the Ligand unit is a Cell Binding Agent that binds to an extracellular
target on a cell. Such a Cell Binding Agent can be a protein, polypeptide, peptide or a non-
peptidic agent. In some embodiments, the Cell Binding Agent may be a protein,
polypeptide or peptide. In some embodiments, the Cell Binding Agent may be a cyclic
polypeptide. The Cell Binding Agent also may be antibody or an antigen-binding fragment
of an antibody. Thus, in one embodiment, the present invention provides an antibody-drug
conjugate (ADC).
In one embodiment the antibody is a monoclonal antibody; chimeric antibody; humanized
antibody; fully human antibody; or a single chain antibody. One embodiment the antibody
is a fragment of one of these antibodies having biological activity. Examples of such
fragments include Fab, Fab', F(ab') and Fv fragments.
The antibody may be a diabody, a domain antibody (DAB) or a single chain antibody.
In one embodiment, the antibody is a monoclonal antibody.
Antibodies for use in the present invention include those antibodies described in
which is incorporated by reference herein in its entirety and for all
purposes. Particularly preferred are those antibodies for tumour-associated antigens.
VIA510441NZPR
304110081
Examples of those antigens known in the art include, but are not limited to, those tumour-
associated antigens set out in . See, for instance, pages 41-55.
In some embodiments, the conjugates are designed to target tumour cells via their cell
surface antigens. The antigens may be cell surface antigens which are either over-
expressed or expressed at abnormal times or cell types. Preferably, the target antigen is
expressed only on proliferative cells (preferably tumour cells); however this is rarely
observed in practice. As a result, target antigens are usually selected on the basis of
differential expression between proliferative and healthy tissue.
Antibodies have been raised to target specific tumour related antigens including:
Cripto, CD19, CD20, CD22, CD30, CD33, Glycoprotein NMB, CanAg, Her2
(ErbB2/Neu), CD56 (NCAM), CD70, CD79, CD138, PSCA, PSMA (prostate specific
membrane antigen), BCMA, E-selectin, EphB2, Melanotransferin, Muc16 and TMEFF2. In
any of the embodiments provided herein, the Ligand unit can be a monoclonal antibody
that specifically binds to the Cripto antigen, CD19 antigen, CD20 antigen, CD22 antigen,
CD30 antigen, CD33 antigen, Glycoprotein NMB, CanAg antigen, Her2 (ErbB2/Neu)
antigen, CD56 (NCAM) antigen, CD70 antigen, CD79 antigen, CD138 antigen, PSCA,
PSMA (prostate specific membrane antigen), BCMA, E-selectin, EphB2, Melanotransferin,
Muc16 antigen or TMEFF2 antigen.
The Ligand unit is connected to the Linker unit. In one embodiment, the Ligand unit is
connected to A, where present, of the Linker unit.
In one embodiment, the connection between the Ligand unit and the Linker unit is through
a thioether bond.
In one embodiment, the connection between the Ligand unit and the Linker unit is through
a disulfide bond.
In one embodiment, the connection between the Ligand unit and the Linker unit is through
an amide bond.
In one embodiment, the connection between the Ligand unit and the Linker unit is through
an ester bond.
VIA510441NZPR
304110081
In one embodiment, the connection between the Ligand unit and the Linker is formed
between a thiol group of a cysteine residue of the Ligand unit and a maleimide group of the
Linker unit.
The cysteine residues of the Ligand unit may be available for reaction with the functional
group of the Linker unit to form a connection. In other embodiments, for example where
the Ligand unit is an antibody, the thiol groups of the antibody may participate in interchain
disulfide bonds. These interchain bonds may be converted to free thiol groups by e.g.
treatment of the antibody with DTT prior to reaction with the functional group of the Linker
unit.
In some embodiments, the cysteine residue is introduced into the heavy or light chain of an
antibody. Positions for cysteine insertion by substitution in antibody heavy or light chains
include those described in Published U.S. Application No. 2007-0092940 and International
Patent Publication WO2008/070593, which are incorporated by reference herein in their
entirety and for all purposes.
Methods of Treatment
The compounds or conjugates of the present invention may be used in a method of
therapy. Also provided is a method of treatment, comprising administering to a subject in
need of treatment a therapeutically-effective amount of a compound of formula I or
conjugate thereof. The term “therapeutically effective amount” is an amount sufficient to
show benefit to a patient. Such benefit may be at least amelioration of at least one
symptom. The actual amount administered, and rate and time-course of administration,
will depend on the nature and severity of what is being treated. Prescription of treatment,
e.g. decisions on dosage, is within the responsibility of general practitioners and other
medical doctors.
A compound or conjugate may be administered alone or in combination with other
treatments, either simultaneously or sequentially dependent upon the condition to be
treated. Examples of treatments and therapies include, but are not limited to,
chemotherapy (the administration of active agents, including, e.g. drugs; surgery; and
radiation therapy.
VIA510441NZPR
304110081
Pharmaceutical compositions according to the present invention, and for use in accordance
with the present invention, may comprise, in addition to the active ingredient, i.e. a
compound of formula I, or conjugate thereof, a pharmaceutically acceptable excipient,
carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such
materials should be non-toxic and should not interfere with the efficacy of the active
ingredient. The precise nature of the carrier or other material will depend on the route of
administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous, or
intravenous.
Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or
liquid form. A tablet may comprise a solid carrier or an adjuvant. Liquid pharmaceutical
compositions generally comprise a liquid carrier such as water, petroleum, animal or
vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other
saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene
glycol may be included. A capsule may comprise a solid carrier such a gelatin.
For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction,
the active ingredient will be in the form of a parenterally acceptable aqueous solution which
is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the
art are well able to prepare suitable solutions using, for example, isotonic vehicles such as
Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives,
stabilisers, buffers, antioxidants and/or other additives may be included, as required.
The Compounds and Conjugates can be used to treat proliferative disease and
autoimmune disease. The term “proliferative disease” pertains to an unwanted or
uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such
as, neoplastic or hyperplastic growth, whether in vitro or in vivo.
Examples of proliferative conditions include, but are not limited to, benign, pre-malignant,
and malignant cellular proliferation, including but not limited to, neoplasms and tumours
(e.g., histocytoma, glioma, astrocyoma, osteoma), cancers (e.g. lung cancer, small cell
lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carinoma, ovarian
carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer,
pancreatic cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma),
leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective
VIA510441NZPR
304110081
tissues), and atherosclerosis. Other cancers of interest include, but are not limited to,
haematological malignancies such as leukemias and lymphomas, such as non-Hodgkin
lymphoma, and subtypes such as DLBCL, marginal zone, mantle zone, and follicular,
Hodgkin lymphoma, AML, and other cancers of B or T cell origin.
Examples of autoimmune disease include the following: rheumatoid arthritis, autoimmune
demyelinative diseases (e.g., multiple sclerosis, allergic encephalomyelitis), psoriatic
arthritis, endocrine ophthalmopathy, uveoretinitis, systemic lupus erythematosus,
myasthenia gravis, Graves’ disease, glomerulonephritis, autoimmune hepatological
disorder, inflammatory bowel disease (e.g., Crohn’s disease), anaphylaxis, allergic
reaction, Sjögren’s syndrome, type I diabetes mellitus, primary biliary cirrhosis, Wegener’s
granulomatosis, fibromyalgia, polymyositis, dermatomyositis, multiple endocrine failure,
Schmidt’s syndrome, autoimmune uveitis, Addison’s disease, adrenalitis, thyroiditis,
Hashimoto’s thyroiditis, autoimmune thyroid disease, pernicious anemia, gastric atrophy,
chronic hepatitis, lupoid hepatitis, atherosclerosis, subacute cutaneous lupus
erythematosus, hypoparathyroidism, Dressler’s syndrome, autoimmune thrombocytopenia,
idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, pemphigus,
dermatitis herpetiformis, alopecia arcata, pemphigoid, scleroderma, progressive systemic
sclerosis, CREST syndrome (calcinosis, Raynaud’s phenomenon, esophageal dysmotility,
sclerodactyly, and telangiectasia), male and female autoimmune infertility, ankylosing
spondolytis, ulcerative colitis, mixed connective tissue disease, polyarteritis nedosa,
systemic necrotizing vasculitis, atopic dermatitis, atopic rhinitis, Goodpasture’s syndrome,
Chagas’ disease, sarcoidosis, rheumatic fever, asthma, recurrent abortion, anti-
phospholipid syndrome, farmer’s lung, erythema multiforme, post cardiotomy syndrome,
Cushing’s syndrome, autoimmune chronic active hepatitis, bird-fancier’s lung, toxic
epidermal necrolysis, Alport’s syndrome, alveolitis, allergic alveolitis, fibrosing alveolitis,
interstitial lung disease, erythema nodosum, pyoderma gangrenosum, transfusion reaction,
Takayasu’s arteritis, polymyalgia rheumatica, temporal arteritis, schistosomiasis, giant cell
arteritis, ascariasis, aspergillosis, Sampter’s syndrome, eczema, lymphomatoid
granulomatosis, Behcet’s disease, Caplan’s syndrome, Kawasaki’s disease, dengue,
encephalomyelitis, endocarditis, endomyocardial fibrosis, endophthalmitis, erythema
elevatum et diutinum, psoriasis, erythroblastosis fetalis, eosinophilic faciitis, Shulman’s
syndrome, Felty’s syndrome, filariasis, cyclitis, chronic cyclitis, heterochronic cyclitis,
Fuch’s cyclitis, IgA nephropathy, Henoch-Schonlein purpura, graft versus host disease,
transplantation rejection, cardiomyopathy, Eaton-Lambert syndrome, relapsing
VIA510441NZPR
304110081
polychondritis, cryoglobulinemia, Waldenstrom’s macroglobulemia, Evan’s syndrome, and
autoimmune gonadal failure.
In some embodiments, the autoimmune disease is a disorder of B lymphocytes (e.g.,
systemic lupus erythematosus, Goodpasture’s syndrome, rheumatoid arthritis, and type I
diabetes), Th1-lymphocytes (e.g., rheumatoid arthritis, multiple sclerosis, psoriasis,
Sjögren’s syndrome, Hashimoto’s thyroiditis, Graves’ disease, primary biliary cirrhosis,
Wegener’s granulomatosis, tuberculosis, or graft versus host disease), or Th2-lymphocytes
(e.g., atopic dermatitis, systemic lupus erythematosus, atopic asthma, rhinoconjunctivitis,
allergic rhinitis, Omenn’s syndrome, systemic sclerosis, or chronic graft versus host
disease). Generally, disorders involving dendritic cells involve disorders of Th1-
lymphocytes or Th2-lymphocytes. In some embodiments, the autoimmunie disorder is a T
cell-mediated immunological disorder.
In some embodiments, the amount of the Conjugate administered ranges from about 0.01
to about 10 mg/kg per dose. In some embodiments, the amount of the Conjugate
administered ranges from about 0.01 to about 5 mg/kg per dose. In some embodiments,
the amount of the Conjugate administerd ranges from about 0.05 to about 5 mg/kg per
dose. In some embodiments, the amount of the Conjugate administerd ranges from about
0.1 to about 5 mg/kg per dose. In some embodiments, the amount of the Conjugate
administered ranges from about 0.1 to about 4 mg/kg per dose. In some embodiments, the
amount of the Conjugate administered ranges from about 0.05 to about 3 mg/kg per dose.
In some embodiments, the amount of the Conjugate administered ranges from about 0.1 to
about 3 mg/kg per dose. In some embodiments, the amount of the Conjugate administered
ranges from about 0.1 to about 2 mg/kg per dose.
Includes Other Forms
Unless otherwise specified, included in the above are the well known ionic, salt, solvate,
and protected forms of these substituents. For example, a reference to carboxylic acid
(-COOH) also includes the anionic (carboxylate) form (-COO ), a salt or solvate thereof, as
well as conventional protected forms. Similarly, a reference to an amino group includes the
+ 1 2
protonated form (-N HR R ), a salt or solvate of the amino group, for example, a
hydrochloride salt, as well as conventional protected forms of an amino group. Similarly, a
reference to a hydroxyl group also includes the anionic form (-O ), a salt or solvate thereof,
as well as conventional protected forms.
VIA510441NZPR
304110081
Salts
It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of
the active compound, for example, a pharmaceutically-acceptable salt. Examples of
pharmaceutically acceptable salts are discussed in Berge, et al., J. Pharm. Sci., 66, 1-19
(1977).
For example, if the compound is anionic, or has a functional group which may be anionic
(e.g. -COOH may be -COO ), then a salt may be formed with a suitable cation. Examples
of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na
+ 2+ 2+ +3
and K , alkaline earth cations such as Ca and Mg , and other cations such as Al .
Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e.
+ + + + +
NH ) and substituted ammonium ions (e.g. NH R , NH R , NHR , NR ). Examples of
4 3 2 2 3 4
some suitable substituted ammonium ions are those derived from: ethylamine,
diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine,
ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline,
meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An
example of a common quaternary ammonium ion is N(CH
If the compound is cationic, or has a functional group which may be cationic (e.g. -NH may
be -NH ), then a salt may be formed with a suitable anion. Examples of suitable inorganic
anions include, but are not limited to, those derived from the following inorganic acids:
hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and
phosphorous.
Examples of suitable organic anions include, but are not limited to, those derived from the
following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic,
camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric,
glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic,
isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic,
palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic,
stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric. Examples of suitable
polymeric organic anions include, but are not limited to, those derived from the following
polymeric acids: tannic acid, carboxymethyl cellulose.
VIA510441NZPR
304110081
Solvates
It may be convenient or desirable to prepare, purify, and/or handle a corresponding solvate
of the active compound. The term “solvate” is used herein in the conventional sense to
refer to a complex of solute (e.g. active compound, salt of active compound) and solvent. If
the solvent is water, the solvate may be conveniently referred to as a hydrate, for example,
a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
Carbinolamines
The invention includes compounds where a solvent adds across the imine bond of the PBD
moiety, which is illustrated below where the solvent is water or an alcohol (R OH, where R
is C alkyl):
H R R A
R OH
N R R
R O O
These forms can be called the carbinolamine and carbinolamine ether forms of the PBD.
The balance of these equilibria depend on the conditions in which the compounds are
found, as well as the nature of the moiety itself.
These particular compounds may be isolated in solid form, for example, by lyophilisation.
Isomers
Certain compounds may exist in one or more particular geometric, optical, enantiomeric,
diasteriomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric
forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms;
endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-)
forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms;
α- and β-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-
forms; and combinations thereof, hereinafter collectively referred to as “isomers” (or
“isomeric forms”).
Note that, except as discussed below for tautomeric forms, specifically excluded from the
term “isomers”, as used herein, are structural (or constitutional) isomers (i.e. isomers which
differ in the connections between atoms rather than merely by the position of atoms in
space). For example, a reference to a methoxy group, -OCH , is not to be construed as a
VIA510441NZPR
304110081
reference to its structural isomer, a hydroxymethyl group, -CH OH. Similarly, a reference
to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-
chlorophenyl. However, a reference to a class of structures may well include structurally
isomeric forms falling within that class (e.g. C alkyl includes n-propyl and iso-propyl; butyl
includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-
methoxyphenyl).
The above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and
enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated
below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime,
thioketone/enethiol, N-nitroso/hyroxyazo, and nitro/aci-nitro.
O OH H
C C CC
keto enol enolate
Note that specifically included in the term “isomer” are compounds with one or more
isotopic substitutions. For example, H may be in any isotopic form, including H, H (D),
3 12 13 14
and H (T); C may be in any isotopic form, including C, C, and C; O may be in any
16 18
isotopic form, including O and O; and the like.
Unless otherwise specified, a reference to a particular compound includes all such isomeric
forms, including (wholly or partially) racemic and other mixtures thereof. Methods for the
preparation (e.g. asymmetric synthesis) and separation (e.g. fractional crystallisation and
chromatographic means) of such isomeric forms are either known in the art or are readily
obtained by adapting the methods taught herein, or known methods, in a known manner.
General synthetic routes
The synthesis of PBD compounds is extensively discussed in the following references,
which discussions are incorporated herein by reference in their entirety and for all
purposes:
a) WO 00/12508 (pages 14 to 30);
b) (pages 3 to 10);
c) (pages 28 to 29); and
d) (pages 30 to 39).
VIA510441NZPR
304110081
Synthesis route
11
The compounds of the present invention, where R and R form a nitrogen-carbon double
bond between the nitrogen and carbon atoms to which they are bound, can be synthesised
from a compound of Formula 2:
Prot
9' 9
Prot
Prot Prot
X' X
Formula 2
7' 7
12 2
6' 6
2 6 7 9 6’ 7’ 9’ 12
where R , R , R , R , R , R , R , R , X, X’ and R” are as defined for compounds of
formula I, Prot is a nitrogen protecting group for synthesis and Prot is a protected oxygen
group for synthesis or an oxo group, by deprotecting the imine bond by standard methods.
The compound produced may be in its carbinolamine or carbinolamine ether form
depending on the solvents used. For example if Prot is Troc and Prot is an oxygen
protecting group for synthesis, then the deprotection is carried out using a Cd/Pb couple to
yield the compound of formula (I). If Prot is SEM, or an analogous group, and Prot is an
an oxo group, then the oxo group can be removed by reduction, which leads to a protected
carbinolamine intermediate, which can then be treated to remove the SEM protecting
group, followed by the elimination of water. The reduction of the compound of Formula 2
can be accomplished by, for example, superhydride or lithium tetraborohydride, whilst a
suitable means for removing the SEM protecting group is treatment with silica gel.
Compounds of formula 2 can be synthesised from a compound of formula 3a:
Prot
9' 9
Prot
Prot Prot
X' X
Formula 3a
7' 7
TfO R
6' 6
2 6 7 9 6’ 7’ 9’
where R , R , R , R , R , R , R , X, X’ and R” are as defined for compounds of formula 2,
by coupling an organometallic derivative comprising R , such as an organoboron
derivative. The organoboron derivative may be a boronate or boronic acid.
Compounds of formula 2 can be synthesised from a compound of formula 3b:
VIA510441NZPR
304110081
Prot
9' 9
Prot
Prot Prot
X' X
Formula 3b
7' 7
R OTf
6' 6
12 6 7 9 6’ 7’ 9’
where R , R , R , R , R , R , R , X, X’ and R” are as defined for compounds of formula 2,
by coupling an organometallic derivative comprising R , such as an organoboron
derivative. The organoboron derivative may be a boronate or boronic acid.
Compounds of formulae 3a and 3b can be synthesised from a compound of formula 4:
Prot
9' 9
Prot
Prot Prot
X' X
Formula 4
7' 7
TfO OTf
6' 6
2 6 7 9 6’ 7’ 9’
where R , R , R , R , R , R , R , X, X’ and R” are as defined for compounds of formula 2,
by coupling about a single equivalent (e.g. 0.9 or 1 to 1.1 or 1.2) of an organometallic
2 12
derivative, such as an organoboron derivative, comprising R or R .
The couplings described above are usually carried out in the presence of a palladium
catalyst, for example Pd(PPh ) , Pd(OCOCH ) , PdCl , Pd (dba) . The coupling may be
3 4 3 2 2 2 3
carried out under standard conditions, or may also be carried out under microwave
conditions.
The two coupling steps are usually carried out sequentially. They may be carried out with
or without purification between the two steps. If no purification is carried out, then the two
steps may be carried out in the same reaction vessel. Purification is usually required after
the second coupling step. Purification of the compound from the undesired by-products
may be carried out by column chromatography or ion-exchange separation.
The synthesis of compounds of formula 4 where Prot is an oxo group and Prot is SEM
are described in detail in WO 00/12508, which is incorporated herein by reference in its
entirety and for all purposes. In particular, reference is made to scheme 7 on page 24,
where the above compound is designated as intermediate P. This method of synthesis is
also described in , which is incorporated herein by reference in its entirety
VIA510441NZPR
304110081
and for all purposes . Further reference is also made to the synthesis of compounds 8a
and 8b in (pages 36 to 45), which is incorporated herein by reference in
its entirety and for all purposes.
The synthesis of compounds of formula 4 where Prot is a protected oxygen group for
synthesis are described in , which synthesis is herein incorporated by
reference.
10’ 11 11’
Compounds of formula I where R and R are H and R and R are SO M, can be
11
synthesised from compounds of formula I where R and R form a nitrogen-carbon double
bond between the nitrogen and carbon atoms to which they are bound, by the addition of
the appropriate bisulphite salt or sulphinate salt, followed by an appropriate purification
step. Further methods are described in GB 2 053 894, which is herein incorporated by
reference.
In some embodiments of the invention, particularly where R bears a substituent that is
OH or CO H, it may be desired in the above methods to add an organometallic derivative
12 12
of R where the substituent group is protected. For example, if R bears CO H, it may be
preferred to join a compound where the carboxy is protected as an ester (e.g. C alkyl
ester) and then deprotect the carboxy group at a later stage in the synthesis. It may even
be deprotected once part of the linker group for making a drug linker has been added.
The OH substituent may be protected by phenol protecting groups as known in the art.
Nitrogen protecting groups for synthesis
Nitrogen protecting groups for synthesis are well known in the art. In the present invention,
the protecting groups of particular interest are carbamate nitrogen protecting groups and
hemi-aminal nitrogen protecting groups.
Carbamate nitrogen protecting groups have the following structure:
R' O O
wherein R’ is R as defined above. A large number of suitable groups are described on
pages 503 to 549 of Greene, T.W. and Wuts, G.M., Protective Groups in Organic
Synthesis, 3 Edition, John Wiley & Sons, Inc., 1999, which is incorporated herein by
reference.
VIA510441NZPR
304110081
Particularly preferred protecting groups include Troc, Teoc, Fmoc, BOC, Doc, Hoc, TcBOC,
1-Adoc and 2-Adoc.
Other possible groups are nitrobenzyloxycarbonyl (e.g. 4- nitrobenzyloxycarbonyl) and 2-
(phenylsulphonyl)ethoxycarbonyl.
Those protecting groups which can be removed with palladium catalysis are not preferred,
e.g. Alloc.
Hemi-aminal nitrogen protecting groups have the following structure:
R' O
wherein R’ is R as defined above. A large number of suitable groups are described on
pages 633 to 647 as amide protecting groups of Greene, T.W. and Wuts, G.M., Protective
Groups in Organic Synthesis, 3 Edition, John Wiley & Sons, Inc., 1999, which is
incorporated herein by reference. The groups disclosed herein can be applied to
compounds of the present invention. Such groups include, but are not limited to, SEM,
MOM, MTM, MEM, BOM, nitro or methoxy substituted BOM, Cl CCH OCH -.
3 2 2
Protected oxygen group for synthesis
Protected oxygen group for synthesis are well known in the art. A large number of suitable
oxygen protecting groups are described on pages 23 to 200 of Greene, T.W. and Wuts,
G.M., Protective Groups in Organic Synthesis, 3 Edition, John Wiley & Sons, Inc., 1999,
which is incorporated herein by reference in its entirety and for all purposes.
Classes of particular interest include silyl ethers, methyl ethers, alkyl ethers, benzyl ethers,
esters, acetates, benzoates, carbonates, and sulfonates.
Preferred oxygen protecting groups include acetates, TBS and THP.
VIA510441NZPR
304110081
Synthesis of Drug Conjugates
Conjugates comprising PBD dimers as described herein can be prepared using the
knowledge of the skilled artisan in combination with the teachings provided herein. For
example, linkers are described in U.S. Patent No. 6,214,345, U.S. Patent No. 7,498,298 as
well as , each of which is incorporated herein by reference in their
entirety and for all purposes. Other linkers can be prepared according to the references
cited herein or as known to the skilled artisan.
Linker-Drug compounds can be prepared according to methods known in the art in
combination with the teachings provided herein. For example, linkage of amine-based X
substituents (of the PBD dimer Drug unit) to active groups of the Linker units can be
performed according to methods generally described in U.S. Patent Nos. 6,214,345 and
7,498,298; and WO 2009-0117531, or as otherwise known to the skilled artisan. Some
examples are shown below.
Antibodies can be conjugated to Linker-Drug compounds as described in Doronina et al.,
Nature Biotechnology, 2003, 21, 778-784). Briefly, antibodies (4-5 mg/mL) in PBS
containing 50 mM sodium borate at pH 7.4 are reduced with tris(carboxyethyl)phosphine
hydrochloride (TCEP) at 37 ºC. The progress of the reaction, which reduces interchain
disulfides, is monitored by reaction with 5,5’-dithiobis(2-nitrobenzoic acid) and allowed to
proceed until the desired level of thiols/mAb is achieved. The reduced antibody is then
cooled to 0°C and alkylated with 1.5 equivalents of maleimide drug-linker per antibody thiol.
After 1 hour, the reaction is quenched by the addition of 5 equivalents of N-acetyl cysteine.
Quenched drug-linker is removed by gel filtration over a PD-10 column. The ADC is then
sterile-filtered through a 0.22 μm syringe filter. Protein concentration can be determined by
spectral analysis at 280 nm and 329 nm, respectively, with correction for the contribution of
drug absorbance at 280 nm. Size exclusion chromatography can be used to determine the
extent of antibody aggregation, and RP-HPLC can be used to determine the levels of
remaining NAC-quenched drug-linker.
Antibodies with introduced cysteine residues can be conjugated to Linker-Drug compounds
as described in International Patent Publication WO2008/070593, which is incorporated by
reference herein in its entirety and for all purposes or as follows. Antibodies containing an
introduced cysteine residue in the heavy chain are fully reduced by adding 10 equivalents
of TCEP and 1 mM EDTA and adjusting the pH to 7.4 with 1M Tris buffer (pH 9.0).
VIA510441NZPR
304110081
Following a 1 hour incubation at 37°C, the reaction is cooled to 22°C and 30 equivalents of
dehydroascorbic acid is added to selectively reoxidize the native disulfides, while leaving
the introduced cysteine in the reduced state. The pH is adjusted to 6.5 with 1M Tris buffer
(pH 3.7) and the reaction is allowed to proceed for 1 hour at 22°C. The pH of the solution
is then raised again to 7.4 by addition of 1 M Tris buffer (pH 9.0). 3.5 equivalents of the
PBD drug linker in DMSO is placed in a suitable container for dilution with propylene glycol
prior to addition to the reaction. To maintain solubility of the PBD drug linker, the antibody
itself is first diluted with propylene glycol to a final concentration of 33% (e.g., if the
antibody solution was in a 60 mL reaction volume, 30 mL of propylene glycol was added).
This same volume of propylene glycol (30 mL in this example) is added to the PBD drug
linker as a diluent. After mixing, the solution of PBD drug linker in propylene glycol is
added to the antibody solution to effect the conjugation; the final concentration of propylene
glycol is 50%. The reaction is allowed to proceed for 30 minutes and then quenched by
addition of 5 equivalents of N-acetyl cysteine. The ADC is purified by ultrafiltration through
a 30 kD membrane. (Note that the concentration of propylene glycol used in the reaction
can be reduced for any particular PBD, as its sole purpose is to maintain solubility of the
drug linker in the aqueous media.)
For halo-acetamide-based Linker-Drug compounds, conjugation can be performed
generally as follows. To a solution of reduced and reoxidized antibodies (having
introduced cysteines in the heavy chain) in 10 mM Tris (pH 7.4), 50 mM NaCl, and 2 mM
DTPA is added 0.5 volumes of propylene glycol. A 10mM solution of acetamide-based
Linker-Drug compound in dimethylacetamide is prepared immediately prior to conjugation.
An equivalent amount of propylene glycol as added to the antibody solution is added to a
6-fold molar excess of the Linker-Drug compound. The dilute Linker-Drug solution is
added to the antibody solution and the pH is adjusted to 8-8.5 using 1 M Tris (pH 9). The
conjugation reaction is allowed to proceed for 45 minutes at 37° C. The conjugation is
verified by reducing and denaturing reversed phase PLRP-S chromatography. Excess
Linker-Drug compound is removed with Quadrasil MP resin and the buffer is exchanged
into 10 mM Tris (pH 7.4), 50 mM NaCl, and 5% propylene glycol using a PD-10 desalting
column.
VIA510441NZPR
304110081
Illustrative synthesis schemes for Drug linkers
The following schemes are illustrative of routes for synthesising drug linkers – the PBD
dimer is shown with specific substituents, and dimer links, but these may be varied within
the scope of the present invention.
Scheme A
MeO C
2 fmoc
O OMe
HN N
H H N
Prot Sub
AcO 2
S1 (i) diphosgene, pyridine
CH Cl , -78 C to 0 C
R O C
1 N N
HN N H
OMe MeO
Prot Sub
S3 R = Fmoc, R = Ac, R = Me
1 2 3
(ii) LiOH, MeOH, THF, H O
S4 R = R = R = H
1 2 3
(iii) MC-OSu, DIPEA, DMF
HO C
H O H
OMe MeO
Prot Sub
where Prot Sub refers to either the OH or CO H phenyl substituent groups or their
protected versions. The protection may be installed in light of the reactions carried out to
introduce the linking unit, and may be removed when appropriate during the synthesis. In
some embodiments, protection would be in place for step (i), but would be removed either
before or after step (ii). In other embodiments, protection would be in place for step (i), but
would be removed either after step (iii).
The glucuronide linker intermediate S1 (reference: Jeffrey et al., Bioconjugate Chemistry,
2006, 17, 831-840) can be treated with diphosgene in dichlroromethane at -78°C to afford
the glucuronide chloroformate, which is then reacted with the PBD dimer S2 dissolved in
CH Cl by dropwise addition. Warming the reaction to 0°C over 2 hours followed by
extraction will yield the compound S3. Treating a solution of S3 in an equal solvent mixture
of MeOH, tetrahydrofuran, and water (cooled to 0°C) with lithium hydroxide monohydrate
VIA510441NZPR
304110081
for 4 hours, followed by reaction with glacial acetic acid will yield the compound S4.
Adding maleimidocaproyl NHS ester to a solution of S4 in DMF, followed by
diisopropylethylamine and stirring at room temperature under nitrogen for 2 hours will yield
the desired drug linker S5.
This approach could also be used with PBD dimers containing aliphatic amines, such as
benzylamine, e.g. S6:
OH/CO H
The methods of Examples 2 and 3 could also be applied to a wide variety of the PBD
dimers of the present invention in order to introduce peptidic linkers.
Further Preferences
The following preferences may apply to all aspects of the invention as described above, or
may relate to a single aspect. The preferences may be combined together in any
combination.
6’ 7’ 9’ 10’ 11’ 6 7 9
In some embodiments, R , R , R , R , R and Y’ are preferably the same as R , R , R ,
11
R , R and Y respectively.
Dimer link
Y and Y’ are preferably O.
R’’ is preferably a C alkylene group with no substituents. More preferably R’’ is a C , C
3-7 3 5
alkylene. Most preferably, R’’ is a C or C alkylene.
or C
7 3 5
R to R
R is preferably H.
R is preferably selected from H, OH, OR, SH, NH , nitro and halo, and is more preferably
H or halo, and most preferably is H.
VIA510441NZPR
304110081
R is preferably selected from H, OH, OR, SH, SR, NH , NHR, NRR’, and halo, and more
preferably independently selected from H, OH and OR, where R is preferably selected from
optionally substituted C alkyl, C heterocyclyl and C aryl groups. R may be more
1-7 3-10 5-10
preferably a C alkyl group, which may or may not be substituted. A substituent of
interest is a C aryl group (e.g. phenyl). Particularly preferred substituents at the 7-
positions are OMe and OCH Ph. Other substituents of particular interest are
dimethylamino (i.e. –NMe ); -(OC H ) OMe, where q is from 0 to 2; nitrogen-containing C
2 2 4 q 6
heterocyclyls, including morpholino, piperidinyl and N-methyl-piperazinyl.
9’ 6’ 7’
These preferences apply to R , R and R respectively.
A in R may be phenyl group or a C heteroaryl group, for example furanyl, thiophenyl and
pyridyl. In some embodiments, A is preferably phenyl. In other embodiments, A is
preferably thiophenyl, for example, thiophenyl and thiophenyl.
, wherein R is selected from the group comprising H and
X is a group selected from NHR
NH NNH
C alkyl, and . In some embodiments, X may preferably be
NHR . X may more preferably be NHMe, NHEt, and NH , and may even more preferably
be: NH .
Q -X may be on any of the available ring atoms of the C aryl group, but is preferably on a
ring atom that is not adjacent the bond to the remainder of the compound, i.e. it is
preferably β or γ to the bond to the remainder of the compound. Therefore, where the C
aryl group (A) is phenyl, the substituent (Q -X) is preferably in the meta- or para- positions,
and more preferably is in the para- position.
In some embodiments, Q is a single bond. In these embodiments, Q is selected from a
single bond and -Z-(CH ) -, where Z is selected from a single bond, O, S and NH and is
from 1 to 3. In some of these embodiments, Q is a single bond. In other embodiments,
Q is -Z-(CH ) -. In these embodiments, Z may be O or S and n may be 1 or n may be 2.
In other of these embodiments, Z may be a single bond and n may be 1.
VIA510441NZPR
304110081
In other embodiments, Q is -CH=CH-.
In some embodiments, R may be -A-CH -X and -A-X. In these embodiments, X may
preferably be NH .
R may be a C aryl group. A C aryl group may be a phenyl group or a C heteroaryl
-7 5-7 5-7
group, for example furanyl, thiophenyl and pyridyl. In some embodiments, R is preferably
phenyl. In other embodiments, R is preferably thiophenyl, for example, thiophenyl and
thiophenyl.
R may be a C aryl, for example a quinolinyl or isoquinolinyl group. The quinolinyl or
8-10
isoquinolinyl group may be bound to the PBD core through any available ring position. For
example, the quinolinyl may be quinolinyl, quinolinyl, quinolin-4yl, quinolinyl,
quinolinyl, quinolinyl and quinolinyl. Of these quinolinyl and quinolinyl may
be preferred. The isoquinolinyl may be isoquinolinyl, isoquinolinyl, isoquinolin-4yl,
isoquinolinyl, isoquinolinyl, isoquinolinyl and isoquinolinyl. Of these isoquinolin-
3-yl and isoquinolinyl may be preferred.
12 O O
R bears a substituent selected from OH, CO H, CO R , where R is selected from C
2 2 1-4
alkyl. The substituent may be any position.
Where R is C aryl group, a single substituent is preferably on a ring atom that is not
adjacent the bond to the remainder of the compound, i.e. it is preferably β or γ to the bond
to the remainder of the compound. Therefore, where the C aryl group is phenyl, the
substituent is preferably in the meta- or para- positions, and more preferably is in the para-
position.
Where R is a C aryl group, for example quinolinyl or isoquinolinyl, it may bear any
8-10
number of substituents at any position of the quinoline or isoquinoline rings.
R is preferably selected from C alkyl, i.e. methyl and ethyl.
VIA510441NZPR
304110081
R groups
Particularly preferred substituted R groups include, but are not limited to, 4-hydroxy-
phenyl, 3-hydroxyphenyl, 4-carboxy-phenyl, 3-carboxy-phenyl, 4-methyloxycarbonyl-
phenyl, 3-methyloxycarbonyl-phenyl, 4-ethyloxycarbonyl-phenyl and 4-ethyloxycarbonyl-
phenyl.
M and z
It is preferred that M and M’ are monovalent pharmaceutically acceptable cations, and are
more preferably Na .
z is preferably 3.
Accordingly, compounds of the present invention include, for example, those of formula I,
or a pharmaceutically acceptable salt or solvate thereof, wherein
(i) R is of formula III:
where A is a phenyl group, X is NHR , wherein R is selected from the group comprising H
and C saturated alkyl, Q is a single bond, and the remainder of the substituents are as
defined herein.
Compounds of the present invention include, for example, those of formula I, or a
pharmaceutically acceptable salt or solvate thereof, wherein
(ii) R is of formula III:
where A is a phenyl group, X is NHR , wherein R is selected from the group comprising H
and C saturated alkyl, Q is a single bond, Q is selected from a single bond and -Z-
(CH ) -, where Z is selected from a single bond and n is from 1 to 3; and the remainder of
the substituents are as defined herein.
(iii) Compounds of the present invention include, for example, those of formula I, or a
pharmaceutically acceptable salt or solvate thereof, wherein R is a phenyl group,
substituted by a group selected from CO H, CO R , where R is selected from saturated
C alkyl; and the remainder of the substituents are as defined herein.
VIA510441NZPR
304110081
(iv) Compounds of the present invention include, for example, those of formula I, or a
pharmaceutically acceptable salt or solvate thereof, wherein R is a phenyl group,
substituted by a group selected from CO H, CO R , where R is selected from methyl or
ethyl; and the remainder of the substituents are as defined herein.
(v) Compounds of the present invention include, for example, those of formula I, or a
pharmaceutically acceptable salt or solvate thereof, wherein
R is of formula III:
where A is a phenyl group, X is NHR , wherein R is selected from the group comprising H
and C saturated alkyl, Q is a single bond, Q is selected from a single bond and -Z-
(CH ) -, where Z is selected from a single bond and n is from 1 to 3; R is a phenyl group,
substituted by a group selected from OH, CO H, CO R , where R is selected from C
2 2 1-4
saturated alkyl; and the remainder of the substituents are as defined herein.
(vi) Compounds of the present invention include, for example, those of formula I, or a
pharmaceutically acceptable salt or solvate thereof, wherein
R is of formula III:
where A is a phenyl group, X is NHR , wherein R is selected from the group comprising H
and C saturated alkyl, Q is a single bond, Q is selected from a single bond and -Z-
(CH ) -, where Z is selected from a single bond and n is from 1 to 3; R is a phenyl group,
substituted by a group selected from CO H, CO R , where R is selected from methyl or
ethyl; and the remainder of the substituents are as defined herein.
Preferred compounds of the present invention include any of those described in (i) through
(vi) wherein:
(a) the substituent group on R is in the meta- or para- position, and more preferably in
the para- position,
(b) Y and Y’ are O,
(c) R’’ is –(CH )- (CH )-(CH )- or -(CH )- (CH )-(CH )-(CH )-(CH )-,
2 2 2 2 2 2 2 2
VIA510441NZPR
304110081
11
(d) R and R form a nitrogen-carbon bond between the nitrogen and carbon atoms to
’ 11’
which they are bound and R and R form a nitrogen-carbon bond between the nitrogen
and carbon atoms to which they are bound,
7 7’
(e) R is methoxy or ethoxy and R is methoxy or ethoxy, or
6 9 6’ 9’
(f) R , R , R , and R are hydrogen, or any combination of (a) through (f).
Particularly preferred compounds of the present invention are of formula Ia:
1a 1a
OR R O
or a pharmaceutically acceptable salt or solvate thereof, where
n is 1 or 3;
R is methyl or phenyl;
R is:
N NHR
or , where R is selected from H and methyl;
R is selected from:
(a) ;
(b) ; and
(c) .
Particularly preferred compounds include:
VIA510441NZPR
304110081
,
,
VIA510441NZPR
304110081
, and
or a pharmaceutically acceptable salt or solvate thereof.
3 aspect
The preferences expressed above for the first aspect may apply to the compounds of this
aspect, where appropriate.
When R is carbamate nitrogen protecting group, it may preferably be Teoc, Fmoc and
Troc, and may more preferably be Troc.
11 O O O
When R is O-Prot , wherein Prot is an oxygen protecting group, Prot may preferably
be TBS or THP, and may more preferably be TBS.
VIA510441NZPR
304110081
When R is a hemi-aminal nitrogen protecting group, it may preferably be MOM, BOM or
SEM, and may more preferably be SEM.
The preferences for compounds of formula I apply as appropriate to D in the sixth aspect of
the invention. For example, in the sixth aspect, the PBD dimer is any of the compounds of
formula I, or a pharmaceutically acceptable salt or solvate thereof, described herein expect
that, is replaced with , is replaced with
, and is replaced with where the wavy line
indicates the point of attachment to the Linker Unit.
Accordingly, the Conjugates of the present invention include those having the following
formula (IV)
L - (LU-D) (IV)
or a pharmaceutically acceptable salt or solvate thereof, wherein L is a Ligand unit (i.e., a
targeting agent), LU is a Linker unit and the PBD dimer D is any of the compounds of
formula I, or a pharmaceutically acceptable salt or solvate thereof, described herein expect
that, is replaced with , is replaced with
, and is replaced with where the wavy line
indicates the point of attachment to the Linker Unit.
(a) Conjugates of the present invention include, for example, those of the formula:
CBA – A – L – *
where the asterisk indicates the point of attachment to the PBD dimer (D) or the
Spacer unit, CBA is the Cell Binding Agent, L is a Specificity unit that is cleavable by the
action of an enzyme, and A is a Stretcher unit connecting L to the Cell Binding Agent.
VIA510441NZPR
304110081
(b) Conjugates of the present invention include, for example, those of the formula:
CBA – A – *
where the asterisk indicates the point of attachment to the PBD dimer (D), CBA is
the Cell Binding Agent, L and A is a Stretcher unit connecting the Drug to the Cell Binding
Agent.
(c) Conjugates of the present invention include, for example, those of the formula:
CBA – A – L – *
where the asterisk indicates the point of attachment to the PBD dimer (D), CBA is
1 1 1
the Cell Binding Agent, A is a Stretcher unit connecting L to the Cell Binding Agent and L
is a Specificity unit that is cleavable by the action of cathepsin, L is a dipeptide, L is a
dipeptide that is cleavable by the action of cathepsin or L is a dipeptide selected from -
Phe-Lys-, -Val-Ala-, -Val-Lys-, -Ala-Lys-, and -Val-Cit-.
Preferred conjugates of the present invention include any of those described in (a) – (c)
wherein A is
where the asterisk indicates the point of attachment to L or D, the wavy line
indicates the point of attachment to CBA, and n is 0 to 6 (preferably n is 5).
Particularly preferred conjugates of the present invention are of formula Ib, lc, 1d, and 1e:
VIA510441NZPR
304110081
or a pharmaceutically acceptable salt or solvate thereof, where
n is 1 or 3;
R is methyl;
R is H
R is selected from:
(a) ;
VIA510441NZPR
304110081
(b) ; and
(c) .
A is a Stretcher unit;
L is a dipeptide that is cleavable by the action of cathepsin;
Ab is an antibody; and
p is from 1 to 20.
In a particularly preferred embodiment of formulas Ib, Ic, Id, and Ie, or a pharmaceutically
acceptable salt or solvate thereof, the connection between the antibody and the Linker Unit
is formed between a thiol group of a cysteine residue of the antibody and a maleimide
group of the Linker unit.
Particularly preferred conjugates include:
VIA510441NZPR
304110081
OMe MeO
CO CH
1 1 2 3
Ab A L
VIA510441NZPR
304110081
N O O
OMe MeO
Ab A L CO CH
or a pharmaceutically acceptable salt or solvate thereof, wherein
n is 1 or 3.
is a Stretcher unit;
L is a dipeptide that is cleavable by the action of cathepsin;
Ab is an antibody; and
p is from 1 to 20.
VIA510441NZPR
304110081
In a particularly preferred embodiment, for all of these preferred conjugates, the connection
between the antibody and the Linker is formed between a thiol group of a cysteine residue
of the antibody and a maleimide group of the Linker unit.
In a particularly preferred embodiment, for all of these preferred conjugates, the antibody is
a monoclonal antibody that specifically binds to the Cripto antigen, CD19 antigen, CD20
antigen, CD22 antigen, CD30 antigen, CD33 antigen, Glycoprotein NMB, CanAg antigen,
Her2 (ErbB2/Neu) antigen, CD56 (NCAM) antigen, CD70 antigen, CD79 antigen, CD138
antigen, PSCA, PSMA (prostate specific membrane antigen), BCMA, E-selectin, EphB2,
Melanotransferin, Muc16 antigen or TMEFF2 antigen.
The preferences for compounds of formula I, or a pharmaceutically acceptable salt or
solvate thereof, apply as appropriate to D in the seventh aspect of the invention. For
example, in the seventh aspect, the PBD dimer is any of the compounds of formula I, or a
pharmaceutically acceptable salt or solvate thereof, described herein expect that, expect
that, is replaced with , is replaced with
, and is replaced with where the wavy line
indicates the point of attachment to the Linker Unit.
Particularly preferred Drug-Linkers of the present invention are of formula If, lg, Ih and Ii:
VIA510441NZPR
304110081
or a pharmaceutically acceptable salt or solvate thereof, where
n is 1 or 3;
R is methyl or phenyl;
R is H
R is selected from:
(a) ;
(b) ; and
(c) .
VIA510441NZPR
304110081
A is a Stretcher unit;and
L is a dipeptide that is cleavable by the action of cathepsin.
Particularly preferred drug- linkers include:
VIA510441NZPR
304110081
VIA510441NZPR
304110081
or a pharmaceutically acceptable salt or solvate thereof, wherein
n is 1 or 3.
A is a Stretcher unit; and
L is a dipeptide that is cleavable by the action of cathepsin.
Examples
General Experimental Methods for Example 1
Optical rotations were measured on an ADP 220 polarimeter (Bellingham Stanley Ltd.) and
concentrations (c) are given in g/100mL. Melting points were measured using a digital
melting point apparatus (Electrothermal). IR spectra were recorded on a Perkin-Elmer
1 13
Spectrum 1000 FT IR Spectrometer. H and C NMR spectra were acquired at 300 K
using a Bruker Avance NMR spectrometer at 400 and 100 MHz, respectively. Chemical
shifts are reported relative to TMS (d = 0.0 ppm), and signals are designated as s (singlet),
d (doublet), t (triplet), dt (double triplet), dd (doublet of doublets), ddd (double doublet of
doublets) or m (multiplet), with coupling constants given in Hertz (Hz). Mass spectroscopy
(MS) data were collected using a Waters Micromass ZQ instrument coupled to a Waters
2695 HPLC with a Waters 2996 PDA. Waters Micromass ZQ parameters used were:
Capillary (kV), 3.38; Cone (V), 35; Extractor (V), 3.0; Source temperature (°C), 100;
Desolvation Temperature (°C), 200; Cone flow rate (L/h), 50; De-solvation flow rate (L/h),
250. High-resolution mass spectroscopy (HRMS) data were recorded on a Waters
Micromass QTOF Global in positive W-mode using metal-coated borosilicate glass tips to
introduce the samples into the instrument. Thin Layer Chromatography (TLC) was
performed on silica gel aluminium plates (Merck 60, F ), and flash chromatography
utilised silica gel (Merck 60, 230-400 mesh ASTM). Except for the HOBt (NovaBiochem)
and solid-supported reagents (Argonaut), all other chemicals and solvents were purchased
from Sigma-Aldrich and were used as supplied without further purification. Anhydrous
solvents were prepared by distillation under a dry nitrogen atmosphere in the presence of
an appropriate drying agent, and were stored over 4Å molecular sieves or sodium wire.
Petroleum ether refers to the fraction boiling at 40-60°C.
General LC/MS conditions: The HPLC (Waters Alliance 2695) was run using a mobile
phase of water (A) (formic acid 0.1%) and acetonitrile (B) (formic acid 0.1%). Gradient:
initial composition 5% B over 1.0 min then 5% B to 95% B within 3 min. The composition
was held for 0.5 min at 95% B, and then returned to 5% B in 0.3 minutes. Total gradient
VIA510441NZPR
304110081
run time equals 5 min. Flow rate 3.0 mL/min, 400 μL was split via a zero dead volume tee
piece which passes into the mass spectrometer. Wavelength detection range: 220 to 400
nm. Function type: diode array (535 scans). Column: Phenomenex Onyx Monolithic C18
50 x 4.60 mm
Example 1
SEM SEM
VIA510441NZPR
304110081
(a) (S)(4-aminophenyl)methoxy(3-((S)methoxy(trifluoromethylsulfonyl)-5,11-
dioxo((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-
c][1,4]benzodiazepinyloxy)pentoxyoxy)((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrolo[2,1-c] [1,4]benzodiazepine-5,11(10H,11aH)-dione (2)
1,1’-[[(Pentane-1,5-diyl)dioxy]bis(11aS)methoxy[[(trifluoromethyl)sulfonyl]oxy]((2-
(trimethylsilyl)ethoxy)methyl)-1,10,11,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]-benzodiazepin-
,11-dione] (1)(Compound 8b in ) (2.8 g, 2.4 mmol, 1eq) was added to a
mixture of sodium carbonate (388 mg, 3.66 mmol, 1.52 eq) and 4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolaneyl)aniline (509 mg, 2.32 mmol, 0.95 eq), in toluene/water/ethanol (20
mL/ 10 mL/10 mL). The reaction flask was flushed with argon and solid Pd(0)tetrakis
triphenylphosphine (84 mg, 0.072 mmol, 0.03 eq) was added. The reaction was allowed to
proceed for 2 hours at 26°C with vigorous stirring under argon. The mixture was partitioned
between ethyl acetate (200 mL) and water (100 mL). The organic phase was washed with
water (100 mL), followed by brine (50 mL). The organic phase was dried over magnesium
sulphate and the volatiles removed by rotoevaporation, followed by hard vacuum. The
residue was purified by flash chromatography (gradient ethyl acetate / hexane, 30/70 up
100/0, v/v). The unsymmetrical amino triflate (2) was isolated in 46% yield (1.23 g). LC/MS
rt 3.80 min m/z (1087.6) M+H. 932 mg (33%) of starting material and 400 mg (16%) of
symmetrical 4-amino phenyl product were also obtained.
(b) (S)((5-(((S)(4-aminophenyl)methoxyoxo-5,11a-dihydro-1H-pyrrolo[2,1-
c][1,4]benzodiazepinyl)oxy)pentyl)oxy)methoxyoxo-5,11a-dihydro-1H-pyrrolo[2,1-
c][1,4]diazepinyl trifluoromethanesulfonate(3)
The amino triflate (2) was dissolved in dry THF (15 mL) and cooled at -78°C (1.2g, 1.1
mmol, 1 eq). A solution of super hydride in THF (1M, 3.3mL, 3.3 mmol, 3 eq) was injected
slowly in the stirred reaction mixture. Reaction completion was observed after 15 minutes.
The reaction mixture was quenched with water (10 mL) and later extracted with DCM (50
mL). The organics were washed with water (100 mL), then brine (50 mL). The organic
phase was dried over magnesium sulphate and the volatiles removed by rotoevaporation,
followed by hard vacuum. The crude carbinolamine (3)(1.10g) was not purified and used
directly in the next step. LC/MS rt 2.68 min m/z (796) M+H for SEM deprotected imine (self-
immolation under the acidic conditions of the LC/MS).
VIA510441NZPR
304110081
(c) (S)(4-aminophenyl)methoxy(5-((S)methoxy(4-methyloxycarbonylphenyl)-
-oxo-5,11a-dihydro- 1H-pyrrolo[2,1-c][1,4]benzodiazepinyloxy)pentyloxy)-1H-
pyrrolo[2,1-c][1,4]benzodiazepine-5(11aH)-one (4)
The crude SEM protected carbinolamine triflate (3) obtained in the previous step (1.10 g, 1
mmol, 1eq) was added to a mixture of sodium carbonate (341 mg, 3.2 mmol, 3.2 eq) and
phenylboronic acid methyl ester (286 mg, 1.6 mmol, 1.6 eq), in
toluene/water/methanol/THF (10 mL/ 5 mL/5 mL/5 mL). The reaction flask was flushed with
argon and solid Pd(0)tetrakis triphenylphosphine (35 mg, 0.030 mmol, 0.03 eq) was added.
The reaction was allowed to proceed overnight with vigorous stirring under argon. The
mixture was partitioned between ethyl acetate (200 mL) and water (100 mL). The organic
phase was washed with water (100 mL), followed by brine (50 mL). The organic phase was
dried over magnesium sulphate and the volatiles removed by rotoevaporation, followed by
hard vacuum. The residue was treated with DCM (50 mL), ethanol (140 mL), water (70
mL) and silica gel (100 g). The viscous mixture was allowed to stir at room temperature for
3 days. The mixture was filtered slowly through a sinter funnel and the silica residue
washed with 90/10 chloroform/methanol v/v (500mL). The organic phase was washed with
water (300 mL), brine (100 mL), dried (magnesium sulphate), filtered, and evaporated in
vacuo to provide the crude material which was purified by flash chromatography (gradient
methanol / chloroform, 0/100 up 4/96, v/v) to yield 200 mg (25%) of PBD dimer LC/MS rt
2.68 min m/z (782) M+H.
General Experimental Methods for Examples 2 to 3
All commercially available anhydrous solvents were used without further purification.
Analytical thin layer chromatography was performed on silica gel 60 F254 aluminum sheets
(EMD Chemicals, Gibbstown, NJ). Radial chromatography was performed on
Chromatotron apparatus (Harris Research, Palo Alto, CA). Analytical HPLC was
performed on a Varian ProStar 210 solvent delivery system configured with a Varian
ProStar 330 PDA detector. Samples were eluted over a C12 Phenomenex Synergi 2.0 x
150 mm, 4 μm, 80 Ǻ reverse-phase column. The acidic mobile phase consisted of
acetonitrile and water both containing 0.1% formic acid. Compounds were eluted with a
linear gradient of acidic acetonitrile from 5% at 1 min post injection, to 95% at 11 min,
followed by isocratic 95% acetonitrile to 15 min (flow rate = 1.0 mL/min). LC-MS was
performed on a ZMD Micromass mass spectrometer interfaced to an HP Agilent 1100
HPLC instrument equipped with a C12 Phenomenex Synergi 2.0 x 150 mm, 4 μm, 80 Å
reverse phase column. The acidic eluent consisted of a linear gradient of acetonitrile from
VIA510441NZPR
304110081
% to 95% in 0.1% aqueous formic acid over 10 min, followed by isocratic 95% acetonitrile
for 5 min (flow rate = 0.4 mL/min). Preparative HPLC was carried out on a Varian ProStar
210 solvent delivery system configured with a Varian ProStar 330 PDA detector. Products
were purified over a C12 Phenomenex Synergi 10.0 x 250 mm, 4 μm, 80 Å reverse phase
column eluting with 0.1% formic acid in water (solvent A) and 0.1% formic acid in
acetonitrile (solvent B). The purification method consisted of the following gradient of
solvent A to solvent B: 90:10 from 0 to 5 min; 90:10 to 10:90 from 5 min to 80 min; followed
by isocratic 10:90 for 5 min. The flow rate was 4.6 mL/min with monitoring at 254 nm.
Example 2
NH OH
(a) (S)((S)(6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)hexanamido)
methylbutanamido)propanoic acid (5)
VIA510441NZPR
304110081
Maleimidocaproyl N-hydroxysuccinimide (1.619 g, 5.25 mmol, 1.05 eq.) and H-Val-Ala-OH
(0.941 g, 5 mmol, 1 eq.) were placed in a 25 mL recovery flask with a stir bar and the flask
was flushed with nitrogen. DMF (4.7 mL) was added and the resulting white slurry was
stirred. DIPEA (0.87 mL, 5 mmol, 1 eq) was added and the mixture was allowed to stir at
room temperature overnight. The mixture was cooled in an ice/water bath and 2M HCl (3
mL, 6 mmol) was added dropwise. The viscous mixture was transferred to a separatory
funnel and the reaction vessel rinsed with sat. NaCl (7 mL), EtOAc (10 mL), sat NaCl (10
mL) and EtOAc (5 mL). After separation of the aqueous phase, it was extracted with
additional EtOAc (2 x 15 mL). The combined organic extracts were washed with sat NaCl
(4 x 15 mL), until the washings were pH ~3.5. The organic extracts were dried over
Na2SO4, filtered and concentrated under reduced pressure to give crude 5 as a white solid
Cl (35 mL) and filtered
(2.172 g, 114% crude yield). Crude 5 was suspended in warm CH
to remove a fine white solid. The solids were rinsed with additional CH Cl (3 mL). Toluene
(5mL) was added and the mixture was cooled in an ice/water bath, which resulted in a thick
slurry. The solids were collected by filtration, washed with a cold mixture of CH Cl (12
mL) and toluene (2 mL) and dried by pulling air through the sample overnight to give 5 as a
white solid (1.327 g, 70% yield). TLC: Rf = 0.26, 10% MeOH in CH Cl . 1H NMR (CDCl )
2 2 3
(ppm) 0.95 (d, J = 17 Hz, 3H), 0.98 (d, J = 17 Hz, 3H), 1.30 (m, 2H), 1.40 (d, J = 17 Hz,
3H), 1.61 (m, 4H), 2.06 (m, 1H), 2.25 (dt, J = 4, 19 Hz, 2H), 3.35 (s, 1H), 3.49 (t, J = 17
Hz,2H), 4.20 (d, J = 18 Hz, 1H), 4.38 (m, 1H), 6.80 (s, 2H). Analytical HPLC (0.1% formic
acid): tR 9.05 min. LC-MS: t 11.17 min, m/z (ES+) found 381.9 (M+H)+, m/z (ES-) found
379.9 (M-H)-.
(b) Methyl 4-((S)((5-(((S)(4-((S)((S)(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)hexanamido)methylbutanamido)propanamido)phenyl)methoxyoxo-5,11a-
dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)oxy)pentyl)oxy)methoxyoxo-
,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)benzoate (6)
A 10 mL flask was charged with 5 (11 mg, 29 μmol), EEDQ (8.9 mg, 36 μmol), and 0.46
mL anhydrous CH Cl . Methanol (24 μL) was added to facilitate dissolution and the
mixture was stirred under nitrogen for 15 min. Aniline 4 (18 mg, 24 μmol) was then added
and the reaction mixture was stirred at room temperature for 4 hours, at which time LC-MS
revealed conversion to product. The reaction was concentrated, dissolved in CH Cl (1
mL) and purified by radial chromatography on a 1 mm chromatotron plate eluted with
VIA510441NZPR
304110081
CH Cl / CH OH mixtures (100:0 to 90:10 CH Cl / CH OH) to provide 6 (9.9 mg, 36%).
2 2 3 2 2 3
Analytical HPLC: t 12.10 min. LC-MS: t 12.91 min, m/z (ES ) found 1145.6 (M+H) .
Example 3
O N OH
N O 2
9: R = H, R = CH
: R = H, R = H
11: R = MC, R = H
Compound 7 was prepared in a similar fashion to compound 5 in Example 2(a) using allyl
chloroformate in place of maleimidocaproyl N-hydroxysuccinimide and dichloromethane as
the reaction solvent.
VIA510441NZPR
304110081
(a) Methyl 4-((S)(3-(((S)(4-((S)((S)(((allyloxy)carbonyl)amino)
methylbutanamido)propanamido)phenyl)methoxyoxo-5,11a-dihydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)oxy)propoxy)methoxyoxo-5,11a-dihydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)benzoate (8)
To a 7 (52 mg, 0.192 mmol) in 5% methanol/dichloromethane (3 mL) was at 0°C was
added EEDQ (47 mg, 0.193 mmol) and the mixture was stirred for 15 minutes before
addition of 4 (50 mg, 0.064 mmol). The reaction mixture was allowed to warm to an
ambient temperature and was monitored by LC-MS. The mixture was aspirated onto a 1
mm radial chromatotron plate and eluted with 1 to 3% methanol/dichloromethane. Product
containing fractions were combined and concentrated to give 43 mg (65%) of 8 as a yellow
solid: MS (ES ) m/z 1036.87 [M+H] .
(b) Methyl 4-((S)(3-(((S)(4-((S)((S)amino
methylbutanamido)propanamido)phenyl)methoxyoxo-5,11a-dihydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)oxy)propoxy)methoxyoxo-5,11a-dihydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)benzoate (9)
To a solution of 8 (43 mg) in anhydrous dichloromethane (3 mL) was added Ph P (0.5 mg,
0.002 mmol), pyrollidine (7 μL, 0.082 mmol) and tetrakis palladium (1.1 mg, 0.001 mmol).
After approximately 30 minutes, the reaction mixture was aspirated onto a 1 mm radial
chromatotron plate and eluted with 5% and then 10% methanol in dichloromethane. The
major band was collected and concentrated under reduced pressure to give 22 mg (56%)
of 9: MS (ES ) m/z 952.5 [M+H] .
(c) 4-((S)(3-(((S)(4-((S)((S)aminomethylbutanamido)propanamido)phenyl)
methoxyoxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)oxy)propoxy)
methoxyoxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)benzoic acid (10)
To 9 (20 mg) in THF/CH OH (2 mL) was added a lithium hydroxide solution (1 mL of a 0.1
M solution). The reaction mixture was stirred at an ambient temperature. At 5 hours, LC-
MS revealed approximately a 30% conversion to desired product with significant
decomposition. The reaction mixture was cooled to -80°C for 16 hours. LC-MS showed a
~1:1 mixture of 10 and 9. The reaction mixture was neutralized with 0.1N HCl (~1 mL) and
was concentrated to approximately 1 mL. DMSO (1 mL) and CH CN (1 mL) were added,
and the mixture was purified by preparatory reverse-phase HPLC. Product containing
fractions were combined, frozen and lyophilized. This resulted in 1.7 mg (9%) of 10 as a
yellow film: MS (ES ) m/z 938 [M+H] .
VIA510441NZPR
304110081
(d) 4-((S)(3-(((S)(4-((S)((S)(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol
yl)hexanamido)methylbutanamido)propanamido)phenyl)methoxyoxo-5,11a-
dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)oxy)propoxy)methoxyoxo-5,11a-
dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)benzoic acid (11)
To a mixture of 10 (1.7 mg, 1.8 μmol) in DMF (100 μL) was added DIPEA (1 μL, 5.75 μmol)
and maleimidocaproyl-NHS ester (4.6 mg, 15 mol). The reaction was monitored by LC-
MS. After 1 hour, the reaction mixture was concentrated under reduced pressure,
dissolved in 0.5 mL of DMSO, 0.5 mL of acetonitrile and 0.5 mL of water, and purified by
preparative reverse-phase HPLC. The product containing fraction was frozen and
lyophilized to give 0.2 mg (10%) of 11: MS (ES ) m/z 1131.6 [M+H] .
Example4
SEM SEM
OMe MeO
SEM SEM
OMe MeO
H N OH
OMe MeO
H N OH
VIA510441NZPR
304110081
(a) (S)(4-aminophenyl)(3-(((S)(4-hydroxyphenyl)methoxy-5,11-dioxo((2-
(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepinyl)oxy)propoxy)methoxy((2-(trimethylsilyl)ethoxy)methyl)-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione (13)
A flask was charged with aniline triflate 12 (compound 9, A1) (520 mg,
490 µmol, 1 eq) dissolved in toluene (5.4 mL), ethanol (2.7 mL), and water (2.7 mL). To
the stirred solution was added 4-hydroxyphenylboronic acid (88 mg, 640 µmol, 1.3 eq),
sodium carbonate (83 mg, 780 µmol, 1.6 eq), and tetrakis(triphenylphosphine)palladium(0)
(23 mg, 20 µmol, 0.04 eq), the reaction was stirred vigorously overnight at room
temperature under nitrogen. After 22 hours the reaction had stalled. Additional
tetrakis(triphenylphosphine)palladium(0) (100 mg, 87 µmol, 0.18 eq) and 4-
hydroxyphenylboronic acid (88 mg, 640 µmol, 1.3 eq) were added and the reaction was
stirred at 35°C for an additional 24 hours, at which time LC/MS revealed conversion to
product. The reaction was concentrated and then partitioned between ethyl acetate (100
mL) and water (100 mL). The aqueous layer was extracted two times with ethyl acetate
(100 mL). The organic layer was then washed with water (100 mL), brine (100 mL), dried
over sodium sulfate, and concentrated to dryness to provide crude SEM dilactam 13. The
crude product was purified by flash chromatography, eluting with mixtures of hexanes:ethyl
acetate (75:25 to 0:100), to provide pure product 13 (218 mg, 44%). LC-MS: t 11.54 min,
+ + 1
m/z (ES ) found 1004.3 (M+H) . H NMR (CDCl ) δ (ppm) 0.02 (s, 18H), 0.98 (m, 4H),
2.44 (m, 2H), 3.12 (m, 2H), 3.67 (m, 3H), 3.77 (m, 4H), 3.91 (m, 8H), 4.29 (t, J = 5.9 Hz,
4H), 4.59 (dt, J = 3.1, 10.2 Hz, 2H), 4.76 (dd, J = 3.1, 10.2 Hz, 2H), 5.52 (d, J = 10.2 Hz,
2H), 6.34 (bs, 1H), 6.66 (d, J = 8.2 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 7.22 (m, 4H), 7.27 (m,
6H), 7.39 (s, 2H).
(b) (S)(4-aminophenyl)(3-(((S)(4-hydroxyphenyl)methoxyoxo-5,11a-dihydro-
1H-benzo[e]pyrrolo[1,2-a][1,4]diazepinyl)oxy)propoxy)methoxy-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepin-5(11aH)-one (14)
A flame-dried flask was charged with SEM dilactam 13 (109 mg, 109 µmol, 1 eq) dissolved
in anhydrous tetrahydrofuran (2.2 mL), and cooled to -78°C. Lithium triethylborohydride
(0.33 mL of a 1 M solution in THF, 330 µmol, 3 eq) was added dropwise and the reaction
was stirred under nitrogen for 2.5 hours, at which time LC revealed incomplete conversion
to product. An additional 0.66 mL of reductant was added and the reaction was stirred for
one more hour. The reaction was quenched through the addition of water (1 mL) and
allowed to warm to room temperature, then diluted brine (25 mL) and extracted three times
VIA510441NZPR
304110081
with dichloromethane (25 mL). The combined organics were washed with brine (25 mL),
dried over sodium sulfate, and evaporated to dryness. The residue was dissolved in a
mixture of dichloromethane (2.8 mL), ethanol (7.4 mL), and water (1.0 mL), and silica gel
(2.7 g) was added. The resulting slurry was stirred at room temperature for 4 days. TLC
analysis revealed conversion to imine dimer 14, at which time the slurry was filtered over a
sintered glass funnel and the silica gel cake was washed with 10% methanol in chloroform
until no further PBD absorbance was observed in the filtrate. Concentration of the filtrate
provided crude imine dimer 14. The material was dissolved in minimal dichloromethane
and purified by radial chromatography on a 1 mm chromatotron plate eluted with
CH Cl /MeOH mixtures (100:0 to 80:20) to provide 14 (31 mg, 40%). LC-MS: t 8.48 min,
2 2 R
m/z (ES ) found 712.2 (M+H) .
6-(2,5-dioxo-2,5-dihydro-1H-pyrrolyl)-N-((S)(((S)((4-((S)(3-(((S)(4-
hydroxyphenyl)methoxyoxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin
yl)oxy)propoxy)methoxyoxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin
yl)phenyl)amino)oxopropanyl)amino)methyloxobutanyl)hexanamide (15)
A flame-dried flask was charged with maleimidocaproyl-valine-alanine linker (Compound
36 of Example 13 in A1) (11 mg, 29 µmol, 1.5 eq) dissolved in 0.8 mL of
% methanol in anhydrous dichloromethane. The acid was pre-activated by addition of N-
ethoxycarbonylethoxy-1,2-dihydroquinoline (9 mg, 34 µmol, 1.8 eq), followed by stirring
at room temperature under nitrogen for 15 minutes. The activated acid was then added to
a flame-dried flask containing PBD dimer 14 (13 mg, 19 µmol, 1 eq). The reaction was
stirred for 4 hours at room temperature under nitrogen, at which time LC-MS revealed
VIA510441NZPR
304110081
conversion to product. The material was diluted in dichloromethane and purified by radial
chromatography on a 1 mm chromatotron plate eluted with CH Cl /MeOH mixtures (100:0
to 80:20) to provide 15 (7.7 mg, 38%). LC-MS: m/z (ES ) found 1075.5 (M+H) .
Example 6 – Preparation of PBD Dimer Conjugates
Antibodies with introduced cysteines: Antibodies to CD70 containing a cysteine residue at
position 239 of the heavy chain were fully reduced by adding 10 equivalents of TCEP and 1
mM EDTA and adjusting the pH to 7.4 with 1M Tris buffer (pH 9.0). Following a 1 hour
incubation at 37°C, the reaction was cooled to 22°C and 30 equivalents of dehydroascorbic
acid were added to selectively reoxidize the native disulfides, while leaving cysteine 239 in
the reduced state. The pH was adjusted to 6.5 with 1M Tris buffer (pH 3.7) and the
reaction was allowed to proceed for 1 hour at 22°C. The pH of the solution was then raised
again to 7.4 by addition of 1 M Tris buffer (pH 9.0). 3.5 equivalents of the PBD drug linker
in DMSO were placed in a suitable container for dilution with propylene glycol prior to
addition to the reaction. To maintain solubility of the PBD drug linker, the antibody itself
was first diluted with propylene glycol to a final concentration of 33% (e.g., if the antibody
solution was in a 60 mL reaction volume, 30 mL of propylene glycol was added). This
same volume of propylene glycol (30 mL in this example) was then added to the PBD drug
linker as a diluent. After mixing, the solution of PBD drug linker in propylene glycol was
added to the antibody solution to effect the conjugation; the final concentration of propylene
glycol is 50%. The reaction was allowed to proceed for 30 minutes and then quenched by
addition of 5 equivalents of N-acetyl cysteine. The ADC was then purified by ultrafiltration
through a 30 kD membrane. (Note that the concentration of propylene glycol used in the
reaction can be reduced for any particular PBD, as its sole purpose is to maintain solubility
of the drug linker in the aqueous media.)
Example 7 - Determination of Free Drug In Vitro Cytotoxicity
Cells as detailed below were collected and plated in 96 well black-sided plates at a density
of 10,000 cells/well in 150 mL of medium. Serial dilutions of the test article (50 mL) were
added, and incubation was carried out for 92 hours at 37°C. After addition of test
compound, cultures were incubated to 96 hours at 37°C. Resazurin (0.25 mM, 50 mL,
Sigma, St. Louis, MO) in medium was added and incubation was continued for 4 hours.
The plates were read on a Fusion HT microplate reader (Packard, Meriden, CT) using an
excitation wavelength of 525 nm and an emission wavelength of 590 nm. Data from all
assays were reduced using GraphPad Prism Version 4 for Windows (GraphPad Software,
VIA510441NZPR
304110081
San Diego, CA). The IC concentrations compared to untreated control cells were
determined using a 4 parameter curve fits.
The IC (pM) values for compounds 4 and 14:
Table 1 – IC50 in pM following 48 hours treatment
compound 786-O Caki-1 HL60 HEL9217
4 50 20 8 8
14 200 400 30 50
Example 8: Determination of In Vitro Activity of Selected Conjugates
The in vitro cytotoxic activity of the selected antibody drug conjugates was assessed using
a resazurin (Sigma, St. Louis, MO, USA) reduction assay (reference: Doronina et al.,
Nature Biotechnology, 2003, 21, 778-784). The antibody drug conjugates were prepared
as described above in Example 6.
For the 96-hour assay, cells cultured in log-phase growth were seeded for 24 hours in 96-
well plates containing 150 μL RPMI 1640 supplemented with 20% FBS. Serial dilutions of
ADC in cell culture media were prepared at 4x working concentration; 50 μL of each
dilution was added to the 96-well plates. Following addition of ADC, the cells were
incubated with test articles for 4 days at 37°C. Resazurin was then added to each well to
achieve a 50 μM final concentration, and the plates were incubated for an additional 4
hours at 37°C. The plates were then read for the extent of dye reduction on a Fusion HT
plate reader (Packard Instruments, Meridien, CT, USA) with excitation and emission
wavelengths of 530 and 590 nm, respectively. The IC value, determined in triplicate, is
defined here as the concentration that results in a 50% reduction in cell growth relative to
untreated controls.
Referring to the tables below, the in vitro cytotoxicity of ADCs using the 96 hour assay is
shown. The ADCs were tested against antigen positive and antigen negative cell lines.
VIA510441NZPR
304110081
Table 2 – IC50 in pM following 96 hours treatment
antigen-negative
ADC drugs/Ab 786-O Caki-1
cell line
h1F6ec-6 1.8 30 0.1 90,000
h1F6ec-11 1.8 50 30 No effect
h1F6ec-15 2.0 30 13 10,000
Example 9: Determination of In Vivo Cytotoxicity of Selected Conjugates
All studies were conducted in accordance with the Animal Care and Use Committee in a
facility that is fully accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care. ADC tolerability was first assessed to ensure that the conjugates
were tolerated at the doses selected for the xenograft experiments. BALB/c mice were
treated with escalating doses of ADC formulated in PBS with 0.5 M arginine and 0.01%
Tween 20. Mice were monitored for weight loss and outward signs of morbidity following
treatment; those that experienced greater than 20% weight loss or displayed signs of
morbidity were euthanized. The antibody used was a CD70 antibody, humanized h1F6
(WO2006/113909), with a point mutation substituting cysteine for serine at position 239.
Conjugation to the Drug Unit is through the introduced cysteine at position 239. An
average of 2 drugs is loaded per antibody.
In vivo therapy experiments were conducted in xenograft models in mice bearing CD70+
renal cell carcinoma or non-Hodgkin lymphoma. Tumor fragments were implanted into
nude mice. Mice were then randomized to study groups with each group averaging around
100 mm . The ADCs were administered according to the schedule indicated. Tumor
volume as a function of time was determined using the formula (L x W )/2. Animals were
euthanized when tumor volumes reached 1000 mm . Mice showing durable regressions
were terminated around day 100 post implant.
Figure 1 shows the results of treatment studies using h1F6ec-compound 6 in CD70+ renal
cell carcinoma (786-O), with single dose given IP. In the figure, ӿ is untreated, ● is
treatment with h1F6ec-6 at 0.03 mg/kg and ○ is treatment with h1F6ec-6 at 0.1 mg/kg.
VIA510441NZPR
304110081
Figure 2 show the results of treatment studies using h1F6ec-compound 6 in non-Hodgkin
lymphoma (MHHPreB1), with dosing q7dx2. In the figure, ӿ is untreated and ● is
treatment with h1F6ec-6 at 0.1 mg/kg.
The results of a mouse tolerability experiment with h1F6ec-6 nominally loaded at 2
drugs/mAb demonstrated that a single dose of 1 mg/kg was well tolerated with no weight
loss or signs of outward morbidity out to 30 days. Administration of a higher dose (2.5
mg/kg) resulted in weight loss.
The IC (nM) values for ADCs with Compound 6:
ADCs 786-O Caki-1 CD70 neg CD70 neg CD70 neg
cancer cancer cancer cell cancer cell cancer cell
cell line cell line line line line
h1F6ec-6
(1.8dr/Ab) 1 0.5 7491 2074 5327
The IC (nM) values for ADCs with Compound 6 and Compound 11:
ADCs 786-O Caki-1 CD70 neg CD70 neg CD70 neg
cancer cancer cell cancer cell cancer cell cancer cell
cell line line line line line
h1F6ec-11
(1.8dr/Ab) 4 2 No Effect 7725
Inh=50%
h1F6ec-6
(1.8dr/Ab) 2 0.01 7215 1415
Inh=45%
Unless the context clearly requires otherwise, throughout the description and the claims,
the words “comprise”, “comprising”, and the like, are to be construed in an inclusive sense
as opposed to an exclusive or exhaustive sense, that is to say, in the sense of “including
but not limited to”.
VIA510441NZPR
304110081
The reference to any prior art in the specification is not, and should not be taken as, an
acknowledgement or any form of suggestion that the prior art forms part of the common
general knowledge in New Zealand.
VIA510441NZPR
304110081
Claims (43)
1. A compound with the formula I: 10' 10 9' 9 11' 11 Y' Y 7' 7 12 2 6' 6 5 or a pharmaceutically acceptable salt or solvate thereof, wherein: is of formula III: NH NNH wherein A is a C aryl group, X is , , or NHR , wherein R is 10 selected from the group consisting of H and C alkyl and either (i) Q is a single bond, and Q is selected from the group consisting of a single bond and - Z-(CH ) -, wherein Z is selected from a single bond, O, S and NH and n is from 1 to 3, or (ii) Q is -CH=CH-, and Q is a single bond; R is a C aryl group, substituted by a group selected from the group consisting of OH, 5-10 15 CO H, and CO R , wherein R is C alkyl; 2 2 1-4 R and R are independently selected from the group consisting of H, R, OH, OR, SH, SR, NH , NHR, NRR’, nitro, Me Sn and halo; wherein R and R’ are independently selected from the group consisting of optionally substituted C alkyl, C heterocyclyl and C aryl groups; 1-12 3-20 5-20 20 R is selected from the group consisting of H, R, OH, OR, SH, SR, NH , NHR, NRR’, nitro, Me Sn and halo; either: 10 11 A A (a) R is H, and R is OH, OR , where R is C alkyl, 10 11 (b) R and R form a nitrogen-carbon double bond between the nitrogen and carbon 25 atoms to which they are bound, or 10 11 (c) R is H and R is SO M, wherein z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R ″ is a C alkylene group, optionally interrupted by one or more heteroatoms, and/or by 3-12 aromatic rings; 30 Y and Y’ are selected from the group consisting of O, S, and NH; VIA510441NZPR 304110081 6’ 7’ 9’ 6 7 9 10’ R , R , R are selected from the same groups as R , R and R , respectively, and R and 11’ 10 11 11 11’ R are the same as R and R , wherein if R and R are SO M, each M is a monovalent pharmaceutically acceptable cation or together represent a divalent pharmaceutically acceptable cation.
2. The compound according to claim 1, wherein R ″ is a C alkylene group, optionally 3-12 N2 N2 interrupted by one or more O, S, NR (where R is H or C alkyl) heteroatoms.
3. The compound according to claim 1 or claim 2, wherein R ″ is a C alkylene group, 3-12 10 optionally interrupted by one or more benzene or pyridine aromatic rings.
4. The compound according to any one of claims 1 to 3, wherein R is selected from the group consisting of H, OH and OR. 15
5. The compound according to claim 4, wherein R is a C alkyloxy group.
6. The compound according to any one of claims 1 to 5, wherein Y is O.
7. The compound according to any one of claims 1 to 6, wherein R’’ is C alkylene.
8. The compound according to any one of claims 1 to 7, wherein R is H.
9. The compound according to any one of claims 1 to 8, wherein R is selected from the group consisting of H and halo.
10. The compound according to any one of claims 1 to 9, wherein A is phenyl.
11. The compound according to any one of claims 1 to 10, wherein X is NH 30
12. The compound according to any one of claims 1 to 11, wherein Q is a single bond.
13. The compound according to claim 12, wherein Q is a single bond.
14. The compound according to claim 12, wherein Q is -Z-(CH ) -, Z is O or S and n is 35 1 or 2. VIA510441NZPR 304110081
15. The compound according to any one of claims 1 to 11, wherein Q is -CH=CH-.
16. The compound according to any one of claims 1 to 15, wherein R is a C aryl 5 group.
17. The compound according to claim 16, wherein R is phenyl.
18. The compound according to any one of claims 1 to 15, wherein R is a C aryl 8-10 10 group.
19. The compound according to any one of claims 1 to 17, wherein R is selected from the group consisting of: 4-hydroxy-phenyl, 3-hydroxyphenyl, 4-carboxy-phenyl, 3-carboxy- phenyl, 4-methyloxycarbonyl-phenyl, 3-methyloxycarbonyl-phenyl, 4-ethyloxycarbonyl- 15 phenyl and 4-ethyloxycarbonyl-phenyl. 10 11
20. The compound according to any one of claims 1 to 19, wherein R and R form a nitrogen-carbon double bond. 6’ 7’ 9’ 10’ 20
21. The compound according to any one of claims 1 to 20, wherein R , R , R , R , 11’ 6 7 9 10 11 R and Y’ are the same as R , R , R , R , R and Y, respectively.
22. The compound according to claim 1, wherein the compound is selected from the group consisting of: VIA510441NZPR 304110081 , and and pharmaceutically acceptable salts or solvates thereof. VIA510441NZPR 304110081
23. A use of a compound according to any one of claims 1 to 22 in the manufacture of a medicament for treating a proliferative disease. 5
24. A compound according to any one of claims 1 to 22 for use in the treatment of a proliferative disease.
25. A compound of formula II: 10' 10 9' 9 11' 11 Y' Y 7' 7 12 2 6' 6 10 wherein: 2 6 7 9 12 6’ 7’ 9’ R , R , R , R , Y, R’’, Y’, R , R , R and R are as defined for a compound of formula I in any one of claims 1 to 20; and either: 10 11 O O (a) R is carbamate nitrogen protecting group, and R is O-Prot , wherein Prot is an 15 oxygen protecting group; or 10 11 (b) R is a hemi-aminal nitrogen protecting group and R is an oxo group; 10’ 11’ 10 11 and R and R are the same as R and R .
26. The compound according to claim 25, wherein R is Troc.
27. The compound according to either claim 25 or claim 26, wherein R is OTBS. 11 10
28. The compound according to 25, wherein R is oxo and R is SEM. 25
29. A Conjugate having formula IV: L - (LU-D) (IV) or a pharmaceutically acceptable salt or solvate thereof; wherein L is a Ligand unit selected from an antibody and an antigen-binding fragment of an antibody; 1 1 1 30 LU is a Linker unit which is -A -L -, wherein A is selected from the group consisting of: VIA510441NZPR 304110081 wherein n is 0 to 6; wherein n is 0 to 6; wherein n is 0 or 1, and m is 0 to 30; and wherein n is 0 or 1, and m is 0 to 30, and wherein in the above A groups the asterisk indicates the point of attachment to L , the 10 wavy line indicates the point of attachment to the Ligand unit; L is a peptide comprising an amino acid sequence which is cleavable by the action of an enzyme, p is 1 to 20; and D is a Drug unit wherein the Drug Unit is a compound according to any one of claims 1 to 15 22, wherein LU is connected to the Drug Unit via the X substituent of R .
30. The Conjugate of claim 29, wherein A is: wherein the asterisk indicates the point of attachment to L , the wavy line indicates the 20 point of attachment to the Ligand unit, and n is 0 to 6. VIA510441NZPR 304110081
31. The Conjugate of claim 30, wherein n is 5.
32. The Conjugate of any one of claims 29 to 31 , wherein L is a dipeptide. 5
33. The Conjugate of claim 32, wherein L is selected from the group consisting of valine-alanine, valine-citrulline and phenylalanine-lysine.
34. The use of a Conjugate according to any one of claims 29 to 33, in the manufacture of a medicament for treating a proliferative disease or an autoimmune disease.
35. The use of claim 34 wherein the cancer is a haematological malignancy and other cancers of B or T cell origin.
36. The use of claim 35 wherein the haematological malignancy is selected from 15 leukemias and/or lymphomas.
37. The use of claim 36 wherein the lymphomas are selected from non-Hodgkin lymphoma and/or Hodgkin lymphoma. 20
38. The use of claim 37 wherein the non-Hodgkin lymphoma is selected from the group consisting of DLBCL, marginal zone, mantle zone, and follicular lymphomas.
39. The use of claim 36 wherein the leukemia is AML. 25
40. The use of claims 34 or 35 wherein the cancer is lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carcinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, a sarcoma, osteosarcoma, Kaposi's sarcoma, or melanoma.
41. A method of treating a non-human mammal having a proliferative disease or an autoimmune disease, comprising administering an effective amount of the Conjugate of any one of claims 29 to 33. 35
42. A drug linker of formula V: VIA510441NZPR 304110081 LU-D (V) or a pharmaceutically acceptable salt or solvate thereof, wherein LU is a Linker unit which 1 1 1 is G -L , wherein G is selected from the group consisting of: 5 wherein n is 0 to 6; wherein n is 0 to 6; wherein n is 0 or 1, and m is 0 to 30; and wherein n is 0 or 1, and m is 0 to 30; and wherein in the above G groups the asterisk indicates the point of attachment to L ; L comprises an amino acid sequence which is cleavable by the action of an enzyme; and D is a Drug unit wherein the Drug Unit is a compound according to any one of claims 1 to 15 22, wherein LU is connected to D via the X substituent of R .
43. A compound as claimed in claim 1 or claim 25, substantially as hereinbefore described with particular reference to any one or more of the Examples and/or
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547195P | 2011-10-14 | 2011-10-14 | |
US61/547,195 | 2011-10-14 | ||
PCT/US2012/059870 WO2013055993A1 (en) | 2011-10-14 | 2012-10-12 | Pyrrolobenzodiazepines and targeted conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623216A NZ623216A (en) | 2016-05-27 |
NZ623216B2 true NZ623216B2 (en) | 2016-08-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10329352B2 (en) | Pyrrolobenzodiazepines and targeted conjugates | |
US10328084B2 (en) | Pyrrolobenzodiazepines and targeted conjugates | |
EP2751110B1 (en) | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases | |
AU2011239525B2 (en) | Pyrrolobenzodiazepines used to treat proliferative diseases | |
EP2751111B1 (en) | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases | |
NZ623216B2 (en) | Pyrrolobenzodiazepines and targeted conjugates |